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ABSTRACT 
Blake Harris Albright: Determinants of AAV Transport Across the Blood-Brain Barrier 
(Under the direction of Aravind Asokan) 
Adeno-associated virus (AAV) is currently the most widely used gene therapy vector for treating 
neurological diseases, showing promising results in preclinical and clinical studies.  Nonetheless, many 
challenges limit effective gene transfer to the central nervous system (CNS) via the vasculature, which 
requires that AAV vectors cross the blood-brain barrier (BBB). As a consequence of sub-optimal 
transduction efficiency, current vectors must be administered at high dosages to achieve therapeutic CNS 
gene transfer and are limited by off-target tissue transduction/sequestration. Thus, developing vectors 
with improved efficiency and specificity is critical towards achieving widespread and therapeutic gene 
transfer to the CNS. This requires a better understanding of the structural determinants for AAV tropism 
and neurovascular transport – which is the primary aim for this dissertation.  To achieve this, we 
generated a chimeric capsid library between two highly homologous serotypes – AAVrh.10, which 
crosses the BBB, and AAV1, which is limited to the vasculature. Through screening individual variants in 
vivo, computational analyses, and rational design, we mapped a footprint from the AAVrh.10 capsid 
which confers BBB transport and widespread CNS transduction when grafted onto AAV1. In this way, 
we engineered the novel and neurotropic AAV1RX capsid, which mediates robust gene transfer 
throughout the brain, with reduced glial and endothelial transduction, and is detargeted from peripheral 
tissues (i.e. liver).  
We hypothesized that the 1RX footprint may alter capsid-sialic acid (SIA) interactions in a way 
that promotes BBB traversal and CNS transduction. We tested this through functional characterization of 
several capsid variants with alterations in their SIA binding site. These capsids were functionally grouped 
according to their differential dependencies on cell-surface SIA for in vitro transduction and binding. 
iv 
Further evaluation in vivo revealed an inverse correlation between capsid-SIA interactions and BBB 
transport/CNS transduction. These experiments suggest that more moderate capsid-SIA interactions may 
facilitate, though only partially explain, the 1RX phenotype. Nonetheless, this led us to propose a 
Goldilocks model wherein the ideal glycan binding affinity, in conjunction with other contributing 
factors, impacts BBB traversal and CNS transduction. Thus, this dissertation sheds light on AAV 
determinants for BBB transport, providing a structure-guided platform for engineering improved CNS-
targeted AAV vectors.  
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CHAPTER 1: INTRODUCTION – AAV BIOLOGY AND USE AS CNS-TARGETED GENE 
THERAPY VECTOR 
1.1. AAV Biology Overview 
In the famous words of Bruce Lee, “Simplicity is brilliance1.” When it comes to viruses, Adeno-
associated virus (AAV) is as simple as they come. Originally discovered as a contaminant in Adenoviral 
preparations in the 1960s, by Atchison and Rowe, AAV is a small (~20 nm) virus characterized by a non-
enveloped icosahedral capsid which contains a 4.7kb single-stranded DNA (ssDNA) genome2–4,. As a 
helper-dependent member of the Parvoviridae family, AAV requires helper gene functions provided by 
co-infection with a helper virus such as Adenovirus or various herpesviruses5–8. In addition to its 
replication-defective nature, AAV is nonpathogenic, yet is able to persist within the host cell, and several 
serotypes are prevalent in the human population8–12. These attributes, in part, make it an ideal candidate 
for gene therapy applications, but also suggest that AAV may have formed an ideal relationship with the 
human host.  Furthermore, because AAV can replicate up to 1 x 106 vg copies per cell, which generally 
causes cell lysis, only during co-infection with a helper virus, it has been theorized that AAV may 
possibly have a beneficial effect on the host by providing protection from other viral infections, i.e. 
Adenovirus or herpesviruses8. 
1.2. AAV Genome & Replication 
As mentioned above, AAV is a remarkably simple virus, which is reflected in the minimalist 
nature of its 4.7 kb ssDNA genome. With a limited coding capacity, the AAV genome consists of the 
nonstructural rep (replication) gene and the structural Cap (capsid) gene, which are flanked by 145 bp 
inverted terminal repeats (ITRs) that form base paired hairpin structures at both ends of the genome8. 
These serve as the only cis requirement for packaging the genome into the capsid13,14. Without a 
repertoire of genes for manipulating the cellular environment, AAV is reliant upon cellular components 
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(i.e. transcriptional machinery) in addition to helper gene functions, for replication and transcription of its 
genome8,15.  
Despite its simplicity, the AAV genome possesses additional complexity in its transcripts, 
accomplished through the use of different promoters, alternative start sites, and alternative splicing8,16,17. 
There are 3 promoters within the AAV genome, two of which control transcription of the rep gene, with 
additional variation due to alternative splicing of a single intron to generate a total of 4 transcripts - 
Rep78, Rep58, Rep52, and Rep408,16,18. Rep78/58 are both transcribed from the p5 promoter and are the 
longest of the transcripts, with the sole difference between the two variants being inclusion and exclusion, 
respectively, of an intron at the 3’-end. The two smaller transcripts, Rep52/40, are transcribed by the p19 
promoter and are similarly differentiated by alternative splicing. 
The cap gene is transcribed by the p40 promoter and generates three transcripts via alternative 
start sites, which in turn produce the structural viral proteins VP1, VP2, and VP319–21. Each of these 
variants possess a shared C terminus, while VP2 and VP1 additionally possess unique N termini, with 
VP1 being the largest of the three21. The AAV capsid is composed of 60 copies of the three capsid 
proteins (CAP) – VP1, VP2, and VP3, assembled in a 1:1:10 stoichiometric ratio. The VP3 protein serves 
as the predominant capsid protein while VP2 is nonessential for capsid assembly; however, the VP1 
unique region (VP1u) possesses phospholipaseA2 activity, which is important for endosomal escape and 
infectivity. Recently, the cap gene of AAV was found to encode an additional (~ 200 amino acid) protein 
encoded by an alternative open reading frame resulting from a +1 frameshift21–26. It was discovered that 
this protein plays a role in capsid assembly, and was accordingly named Assembly-activating protein 
(AAP). Interestingly, AAP is found to be essential for capsid assembly, in a serotype-dependent manner. 
While the mechanism for AAP-mediated capsid assembly is unknown, it possesses an NLS and recent 
studies have suggested that it may play a role as a chaperone to bring AAV capsid proteins to the 
nucleus25–27. Very recently, our lab has mapped the functional domains required for AAP activity, 
identifying linker domains which can be replaced with alternative domains to facilitate engineering new 
functions onto AAP28.  
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The first step for replication of the AAV genome is second-strand synthesis, which converts the 
ssDNA genome into a transcriptionally competent double-stranded DNA (dsDNA) template8,29,30. The 
next step is transcription of the rep genes. Transcriptional repression by Rep78/58 is lifted when Ad 
helper genes allow for Rep-mediated activation of AAV promoters8,31,32. The ITRs serve as the origin of 
replication for the AAV genome, containing a rep binding site for Rep-mediated activation, and 
additionally providing a base-paired free 3’-hydroxyl group which allows DNA synthesis to occur8,32,33. 
Subsequent replication of the ITR occurs, mediated by binding of Rep and nicking at the terminal 
resolution site within the ITR sequence, to facilitate fidelity of ITR replication and to generate a new free 
3’-hydroxyl group for subsequent rounds of replication8,29,30. Replication of the AAV genome is known to 
produce two products due to resolution of the ITR – a dsDNA molecule and a displaced ssDNA molecule.  
Productive AAV infection requires helper gene functions which aid in AAV replication, from 
helper viruses such as Ad and HSV6,8. These essential helper genes are E1a/b, E2a, E4, and the viral 
associated RNA (VAI RNA)8,15,34. The E1a gene product is a transactivator which relieves repression for 
the AAV p5 promoter8,15. Briefly, the proteins encoded by these helper genes function to activate, 
promote, and ensure processivity of replication and transcription of the AAV genome, while the VA RNA 
is thought to promote translation of AAV transcripts35. Importantly, these helper functions can be 
provided in trans for virus production15.  
1.3. AAV Lifecycle 
The first step in the lifecycle of AAV is binding to the cell surface, which is facilitated by 
recognition of primary glycan receptors19,36. The identity of the glycan recognized varies depending on 
the serotype. After binding to the cell surface, uptake occurs, generally via endocytosis through clathrin-
coated pits22,37. Importantly, several secondary co-receptors have been identified, which differ for each 
serotype and enhance transduction, likely through facilitating uptake. Examples include integrins for 
AAV2 & 9, as well as various growth factor receptors (i.e. Fibroblast growth factor receptor for AAV2 & 
4, hepatocyte growth factor receptor (for AAV2 & 3), platelet-derived growth factor receptor (for AAV5) 
and epidermal growth-factor receptor for AAV6)21,38–46. AAV virions then traffic through the endosomal 
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pathway before escaping from early endosomes into the cytosol, a process dependent on the pH-
dependent phospholipase A2 domain on VP122–24,47,48. The virion is then thought to traffic through the 
trans-golgi network before undergoing nuclear import and subsequent trafficking to the nucleolus, where 
capsid uncoating and viral genome release occurs8,22,37,46,49. Second-strand synthesis, a rate-limiting step in 
the pathway, then occurs in order to generate a transcriptionally competent template for subsequent 
transduction and replication steps22. Following replication, both + and – strands are packaged into newly 
formed AAV capsids at equal efficiencies8. It is also important to note that AAV depends upon the host 
cell machinery for both transcription and translation. 
AAV is capable of persisting in the host cell as an episome, enabling long-term gene expression, 
and is also able to enter a latent phase which is characterized by targeted genomic integration50,51. The 
AAV genome integrates into a specific locus on the short arm of chromosome 19, designated the AAVS1 
site52. Importantly, integration is dependent on the Rep protein and occurs only for WT virus in the 
presence of Rep and helper genes, and thus does not occur for recombinant viral vectors53.  
There are also several rate-limiting steps along the AAV transduction pathway that have been 
identified. Briefly, these include trafficking of the capsid to the nucleus22, the rate of capsid uncoating and 
subsequent release of the viral genome, and second-strand synthesis to generate a dsDNA molecule that 
can be transcribed8,22,29. The requirement for second-strand synthesis can be overcome through production 
of self-complementary AAV vectors. These are generated through deletion of the terminal resolution site, 
a sequence in the ITR, which is required for resolving replication. This deletion enables formation of a 
partially dsDNA genome packaged into the capsid, bypassing the second-strand synthesis step required 
for the usual single-stranded genome29,30. Lastly, stability of the vector genome is also known to affect 
transduction8.  
1.4. AAV Capsid Structure 
The AAV capsid is a small (~20nm) icosahedron composed of 60 VP monomers - VP1, VP2 & 
VP3, assembled in a 1:1:10 stoichiometric ratio19. The capsid has a T=1 symmetry (where T is the 
triangulation number), meaning the icosahedron consists of 12 pentameric clusters of capsid subunits. The 
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predominant VP3 monomer is composed of a highly conserved core β-barrel jellyroll structure which 
consists of 8 antiparallel βsheets (βB-H) and a similarly conserved α-helix (αA) (Fig. 1.1.)19,20,54. These 
strands are connected by interdigitating loop regions that are highly variable in sequence identity and are 
identified based upon the strands they connect. This basic structure is conserved across both 
dependoviruses as well as the autonomous parvoviruses19,55,56. The loops are surface-exposed on the full 
60mer particle and their interactions dictate the surface topology on the capsid. Consequently, these 
surface loops are critical determinants of tropism, antigenicity, and receptor usage across capsid 
serotypes19,57–59. 
Furthermore, nine highly variable regions (VRs) are detected in sequence alignments of the 
primary amino acid sequences across various capsid proteins from various AAV serotypes19,57. They are 
easily demarcated from the more conserved regions in these alignments. These VR regions, labeled VR-I 
through VR-IX, vary in length from just a few to a couple hundred amino acids in length. The residues in 
these VRs overlap with the loop regions between β-strands, and diversity in these VRs dictates nearly all 
phenotypic differences between various AAV capsid serotypes. 
The full length amino acid sequence of VP1 is ~736 amino acids, varying based on relative 
deletions and/or insertions present across different serotypes. VP1, VP2 and VP3 possess a shared C-
terminus; however, VP2 and VP3 are differentially truncated and thus possess different N termini. The 
VP1 unique N-terminal region is ~140 residues, which is absent in the truncated VP2 sequence (full VP2 
length is ~600 amino acids)19,21,23,47,60,61. The further truncated VP3 sequence begins around residue 217 of 
the VP1 sequence, and consists of the latter ~520 residues of the VP1 sequence, which again varies across 
serotypes.  
Much of the work dissecting AAV capsid structure and correlating structure with function has 
been done through genetic modification of capsids and through solving capsid structures using X-ray 
crystallography and/or cryo-EM. Structures have been solved for many of the common serotypes (i.e. 
AAV1-AAV9), and even for some capsid-receptor pairs19,60,69–71,61–68. As mentioned before, the AAV 
capsid is composed primarily of the VP3 monomer. This is reflected in the inability to obtain 
6 
crystallographic information for the asymmetrically incorporated VP1 and VP2 monomers, which appear 
disordered on the inside of the capsid19,68. Thus, structures have been solved for the VP3 capsid 
interactions, neglecting the VP1 and VP2 molecules. It is also of note, that the VP1/2 unique regions are 
not known to directly impact features such as tropism, antigenicity, and receptor usage. Rather, these 
determinants seem to reside on the VP3 sequence. Nonetheless, the phospholipase A2 domain of the 
VP1u region is critical for infectivity21,23,47,54,72. 
The interactions between the loops of each monomer manifest as various landmark structures that 
are recognizable on the various axes of symmetry at the capsid surface (Fig. 1.2.). The 5-fold axis of 
symmetry is a pentamer of VP3 monomers characterized by a cylindrical pore, formed by interactions 
between the DE loops (corresponding to VR-II) of monomers, and is encircled by a local depression 
formed largely by interactions involving the HI loop21,73–75 This region is known to be important for 
capsid assembly and for packaging of the viral genome into the capsid, with the viral genome thought to 
be inserted through the 5-fold pore54,76.  
The 3-fold axis of symmetry is formed by a VP3 trimer and is characterized by three large surface 
protrusions, formed from interactions between residues within the BC, EF and GH loops (corresponding 
to VR-IV, VR-V, VR-VI, and VR-VIII) on VP monomers, with the GH loops specifically contributing to 
the three-fold protrusions19,55,57,77,78. These protrusions, or spikes, have been identified as perhaps the most 
significant region on the capsid for affecting capsid-host interactions, dictating tropism, transduction and 
antigenicity. Likewise, the clustered VR-IV, VR-V, VR-VI, and VR-VIII localized to the spikes are key 
targets for mutagenesis to affect these phenotypes and dictate differences between serotypes. For 
example, structural studies have demonstrated that while most of the common AAV serotypes have 
relatively sharp protrusions jutting out at the 3-fold axis, some serotypes (i.e. AAV4) display more 
rounded protrusions, which can be accounted for by sequence variations at these regions21,57,59,79,80. 
Recent structural studies have revealed the glycan receptor binding sites (aka footprints) for 
several AAV capsid-glycan pairs. For instance, the precise residues in such receptor footprints have been 
identified by co-crystallography studies for the AAV1/6-SIA complexes, for the AAV4-mucin complex, 
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for the AAV5-SIA complex, and for the AAV9-GAL complex12,36,38,64,68,81–85. Each of these capsids have 
been found to bind their respective glycan receptors either on or near the three-fold protrusions. The 
binding pocket for each pair accordingly involves many of the same amino acid residues, most of which 
are present in VR-IV, VR-V, VR-VI, and VR-VIII, as well as several residues in VR-I. Nonetheless, there 
is some variation in the precise residues involved, directly and indirectly, in glycan binding. 
The 2-fold axis of symmetry is characterized by a topological depression at the interface between 
two trimers19,20,55,72. This 2-fold channel, also known as the 2-fold dimple, is formed by interactions 
between VR-I and VR-IX on adjacent monomers, with the α-A helix contributing to formation of the wall 
lining the 2-fold depression19,57,72,86. The residues composing VR-I, from the B-E loop on the monomer, 
are also clustered at the shoulder near the base of the three-fold protrusions.  
1.5. Background on Natural AAV Serotypes 
A large array of AAV variants exist, both natural and synthetic12,20,87–89. The more common of the 
natural serotypes discovered include AAV1-AAV9. Out of these, AAV2 is by far the most highly 
characterized and has historically served as the representative model for most of the studies that have 
dissected the molecular biology of AAV, elucidating replication and transduction pathways amongst other 
steps in the AAV lifecycle90. The numerous natural serotypes discovered thus far display broad tropisms 
at the species, tissue, and cellular levels in addition to broad antigenic profiles12.   
In recent years, hundreds of AAV sequences have been isolated from various species. For the 
most part, these variants were isolated from mostly human and non-human primates (i.e. rhesus 
macaques), but new AAV sequences have also been isolated from many other species, including bovine, 
avian, and reptilian species88,89,91–93. AAV2/3/5/6/9 were all isolated from human hosts, while 
AAV1/7/8/9, as well as AAVrh.10/rh.8 were all isolated from non-human primates11,88,94,95. The numerous 
natural serotypes discovered thus far have been categorized phylogenetically based on their capsid amino 
acid sequences and have been organized into several clades along this phylogeny88. While each of the 
main clades is represented by a relatively common AAV serotype (AAV1/6 in clade A, AAV2 in clade B, 
AAV2/3 in clade C, AAV7 in Clade D, AAV8 in clade E, and AAV9 in clade F), each also includes 
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varying numbers of human-derived and non-human primate-derived variants. AAV4 and AAV5, 
however, diverge significantly from most of the other capsids and fall outside of these clades. Due to their 
low sequence homology to other AAV serotypes, pre-existing immunity to the AAV4 and AAV5 
serotypes is rare in the human population74,96. Additionally, AAV4 and AAV5 have more rounded 
protrusions at their 3-fold axes of symmetry, compared to the spikier versions of most other capsids57,71,96. 
Here, we will briefly discuss the various tropisms and transduction profiles for some of these 
common serotypes. When delivered systemically, AAV1 transduces mostly the vasculature in various 
tissues and is generally unable to cross the vascular wall97–99. Nonetheless, AAV1 efficiently transduces 
skeletal muscle and can also transduce neurons and glia in the CNS, following direct intramuscular or 
intracranial injections, respectively100–103. AAV2 is similar in that it transduces cells in various tissues, 
particularly photoreceptors in the eye, with moderate efficiency104–106, but generally relies on direct 
injections into tissue, performing poorly when administered systemically. AAV2 performs exceptionally 
well in cell culture, however. AAV3 and AAV8 both transduce the liver at high levels, and are being 
pursued for liver-targeted gene therapy applications107–110. In humanized murine models, however, AAV3 
preferentially transduces human hepatocytes, while AAV8 prefers murine hepatocytes111. AAV8 
additionally transduces skeletal muscle as well as pancreatic and cardiac tissues109.  Similar to AAV1, 
AAV6/7 both transduce skeletal muscle at high levels following intramuscular injections; however, 
AAV7 is also capable of transducing the CNS following systemic administration98,112. AAV4 exhibits a 
pronounced cardiopulmonary tropism following systemic administration85,112,113. AAV9 is interesting, as 
it transduces nearly all tissues very efficiently following systemic administration, outperforming nearly all 
of the other common serotypes in any given tissue112,114,115. Thus, AAV9 is a great example of the tradeoff 
between efficiency and specificity. Likewise, another serotype, AAVrh.10 (isolated from a rhesus 
macaque) behaves very similarly to AAV9 in this regard98.  
1.6. Glycan Interactions and Receptor Usage 
As previously stated, cell-surface attachment is the first and most crucial step in AAV 
infection/transduction. Binding to the cell surface largely relies on recognition of primary glycan 
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receptors. Thus, receptor usage is a key determinant for tropism as well as transduction, and AAV capsids 
are known to utilize several different glycans for attachment19,56. For instance, AAV2 and AAV3 both 
recognize heparan sulfate proteoglycan (HSPG), and the AAV2-HSPG interaction is historically the most 
characterized capsid-glycan interaction63,116.  
Sialic acid (SIA), in various linkages, is a common receptor for multiple AAV serotypes, 
including AAV1, AAV4, AAV5, and AAV6. AAV1 recognizes α2,3- and α2,6-N-linked SIA, whereas 
AAV5 recognizes only α2,3-N-linked SIA117,118. The AAV6 capsid recognizes both HSPG as well as 
α2,3- and α2,6-N-linked SIA117,118. While these capsid variants all recognize SIA in varying N-linkages, 
AAV4 is the only variant so far that has been shown to utilize α-2,3-O-linked SIA  (also known as 
mucin)85. Previous studies from our lab have identified galactose (GAL) as the primary receptor for 
AAV981. A sulfated N-acetyllactosamine (LacNac) was recently identified as the receptor for AAVrh.10, 
a variant which shares many attributes with AAV9119. Lastly, contrary to the glycoprotein receptors 
discussed so far, a glycolipid (ganglioside) was found to be the receptor for bovine AAV (BAAV)120,121. 
Nonetheless, the primary receptors for many other AAV variants remain unknown, i.e. AAV7/8 for 
instance.  
Structural studies involving cryo-EM and X-ray crystallography, along with mutational analyses, 
have additionally identified the precise residues of the receptor footprints for several capsids38. For 
instance, we know that the binding site for HSPG on AAV2 is located at the 3-fold spikes, utilizing 
several basic residues (R484, R585, R487, K532, and R588)116.  Additionally, critical residues for binding 
HSPG have been identified for AAV3 (R594) and for AAV6 (K459 and K531), which do not overlap 
with the AAV2-HS 63,116,122. The receptor footprint for AAV4 has been determined and found to be 
located at the tip of the 3-fold spikes, where K492, K503, M523, G581, Q583, and N585 were found to be 
the critical residues for binding O-SIA57,85,96,113. The receptor footprint for AAV5 is uniquely located at 
the depression between the spikes at the center of the 3-fold axis of symmetry and includes residues 
M569, A570, T571, G583, T584, Y585, N586, and L58783. 
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The most important receptor footprint in regards to this dissertation is the SIA binding pocket 
shared by AAV1 and AAV6, which is located at the base of the three-fold protrusions117. This footprint is 
comprised of 11 critical amino acid residues, including S268, D270, N271, Y445, G470, S472, V473, 
N500, T502, and W503. Importantly, only 6/11 of these residues are involved in directly contacting the 
SIA (N447S G470, S472, V473, N500 T502, and W503). Interestingly, this footprint is analogous to the 
GAL binding pocket on AAV9. The GAL footprint on AAV9 is localized to the same pocket at the base 
of the 3-fold protrusions and includes the equivalent residues82. However, the precise amino acid residues 
of the AAV9 sequence differ at several of these positions (S269, D271, N272, Y446, S448, T471, A473, 
N474, N501, A503, and W504). Both of these binding pockets involve residues derived from VR-I, VR-
IV, and VR-V regions of the VP3 monomer, and the pocket is formed by interactions between loops of 
two different monomers.  
For each of the capsid-glycan interactions described here, the residues and capsid regions 
involved in binding glycan receptors had also previously been implicated as determinants for 
transduction, tropism, and/or antigenicity38,123. This further stresses the role glycan receptor usage has on 
determining these attributes and reinforces these regions as key structure-function correlates. 
Many other, autonomous, members of the parvovirus family also utilize various forms and 
linkages of SIA as receptors. For instance, Bocavirus recognizes α2,3-N-linked and α2,3-O-linked SIA, 
minute virus of mice (MVM) recognizes α2,3- and α2,8-N-linked SIA, and both canine (CPV) and feline 
(FPV) parvoviruses recognize SIA variants as well56.  Furthermore, AAV shares several structural 
features in common with the autonomous parvoviruses involved in capsid-SIA interactions. For example, 
several parvoviruses (i.e. MVM & CPV) are known to bind SIA in a pocket localized to the 2-fold 
depression, while others, such as the B19 parvovirus bind SIA in a pocket located at the three-fold 
depressions38,55,72,123. While the SIA binding site of AAV is located at the base of the 3-fold protrusions, it 
should be noted that this site is adjacent to the 3-fold depression and in close proximity to the 2-fold 
depression19,56. Thus, despite some variation, the SIA binding sites across these parvovirus variants are 
located at nearby regions of the capsid surface.  
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In addition to primary glycan receptors, subsequent binding to secondary co-receptors has also 
been identified as another important step for transduction8,21,38. The nature of such factors have been 
identified for several AAV variants. These interactions are thought to further facilitate cellular uptake, 
and generally involve various growth factor receptors or integrins. For example, secondary co-receptors 
include fibroblast growth factor receptor (FGFR) for AAV2, hepatocyte growth factor receptor (HGFR) 
for both AAV2 and AAV3, platelet-derived growth factor receptor (PDGFR) for AAV5, and epidermal 
growth factor receptor (EGFR) for AAV640–42,107,124. Additionally, α5β5 integrins have been identified as 
important co-receptors for AAV2 and AAV9, while the 37/67-kDa laminin receptor has been found to be 
a co-receptor for AAV2/3/8/943,46,125. However, no co-receptor has been identified for some serotypes, like 
AAV4 and AAV7.  
In addition to these primary glycan receptors and secondary co-receptors, a previously 
uncharacterized transmembrane protein, (KIAA0319L), was recently identified as a universal receptor for 
AAV. This protein has thus been dubbed the AAV receptor (AAVR)126. While the precise mechanism of 
how AAVR impacts transduction remains to be clarified, it is thought to facilitate endocytosis and 
subsequent cellular trafficking. Furthermore, the relative role played by AAVR alongside primary glycan 
and secondary co-receptors remains contentious.  
Lastly, elucidation of these structure-function correlates for glycan receptor usage has afforded 
our lab and others the ability to rationally engineer these footprints in order to generate novel AAV 
capsids for both gene therapy applications as well as for basic studies aimed at further expanding our 
understanding of AAV biology and capsid-glycan interactions38. Historically, such modification of 
receptor footprints focused on the AAV2 HSPG binding site, but our lab has generated novel AAV4 and 
AAV9-based vectors with altered mucin and GAL interactions that result in unique phenotypes, which 
will be discussed in a later section.  
1.7. Gene Therapy and AAV Vectors 
Background on Gene Therapy Using AAV Vectors. The principal concept behind gene therapy is 
to deliver and express a therapeutic transgene in target tissues and cell types in order to treat a disease 
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characterized by an underlying genetic component. For example, in patients afflicted with a disease 
caused by loss-of-function mutations in a specific gene, the disease may be corrected by delivery of a 
functional copy of the respective gene.  While there are many ways to achieve in vivo gene delivery (i.e. 
directly administering cDNA, using lipid nanoparticles, etc.), viral vectors are often the most effective 
means by which to deliver therapeutic transgenes11,12,127–131. Many other viruses have also been evaluated 
as gene therapy vectors, such as Adenovirus, paramyxoviruses, and the more prominent lentivirus132–137. 
For the most part, these other viral vectors have been met with concern regarding their safety profile and 
efficacy; however, lentiviral vectors remain a promising tool for gene therapy applications in which 
chromosomal integration is required – particularly for ex vivo applications through genetically modifying 
patient-derived cells for combination gene and cell therapies, such as for hematopoietic stem cells. 
Nonetheless, AAV is the leading gene therapy vector.  
Several of its favorable attributes make AAV an ideal viral vector for gene therapy applications. 
Chief amongst these is its inherent lack of pathogenicity and replication-defective nature12,138,139. 
Additionally, AAV infects both dividing and non-dividing cells, and is able to sustain long-term gene 
expression in vivo by persisting as an episome within host cells. AAV has an exceptional safety profile, 
with a lack of integration for the recombinant virus and a favorable immune response8,140. The large array 
of serotypes which display broad tropisms further provide a large toolbox of capsid reagents for targeting 
different tissues12. Furthermore, ability to generate high titers of recombinant virus carrying therapeutic 
transgene cassettes and the relative scalability of production methods further make AAV an ideal viral 
vector, providing the potential to treat a vast number of monogenetic and familial diseases, or any disease 
which is treatable by delivery of a therapeutic transgene, afflicting nearly any tissue11,12,141.  
In 2018, AAV is currently the premiere viral vector for gene therapy applications. To date, there 
have been over 2500 gene therapy clinical trials and two AAV gene therapy products have made it to the 
marketplace, one in Europe and the second in the United States142. Additionally, the past several years 
have seen a mushrooming of biotech companies emerging and/or incorporating gene therapy-focused 
pipelines using AAV vectors to target numerous indications. AAV made its commercial debut in 
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European markets with the release of Glybera® (aka Alipogene tiparvovec) a gene therapy for the 
treatment of familial lipoprotein lipase deficiency, which was developed by uniQure and released in 
European markets in 2012. Glybera utilizes a single intramuscular injection of an AAV1 capsid to deliver 
the human lipoprotein lipase gene to muscle cells in order to treat lipoprotein lipase deficiency142–144. Due 
to current challenges with vector production, it is also important to note that Glybera is currently the most 
expensive drug in the world, fetching a price around $1,000,000. Furthermore, 2017 became a landmark 
year for the gene therapy industry, as Luxturna became the first FDA-approved gene therapy using AAV. 
Luxturna (aka voretigene neparvovec-ryzl) was developed by Spark Therapeutics to treat Leber’s 
congenital amaurosis, utilizing subretinal injections of an AAV2-based vector to deliver a functional copy 
of the RPE65 gene to retinal cells with biallelic RPE65 mutations142,145. Luxturna offers incredible 
restoration of vision for patients with this inherited disease; however, like Glybera, is incredibly costly, 
amounting to over $4,000 per eye146.  
Gene therapy using AAV vectors is being pursued for numerous indications which are currently 
being evaluated in preclinical and clinical studies142. AAV-mediated gene therapy has shown remarkable 
potential towards the treatment of numerous diseases with a genetic basis. Examples range from 
neuromuscular disorders, such as Duchenne muscular dystrophy (DMD) and spinal muscular atrophy 
(SMA), to neurocardiovascular diseases such as Friedrich’s ataxia, and cardiovascular diseases11,147–151. 
For example, phase III clinical trials are underway for an AAV9 vector developed by Avexis to treat 
SMA by delivering a functional copy of the SMN gene to motor neurons following both intravenous and 
intrathecal administration152–154. AAV vectors are being developed and evaluated by multiple companies 
to treat Friedrich’s Ataxia (FA) and FA-associated cardiomyopathy by using an AAV vector to deliver a 
therapeutic frataxin transgene via systemic administration. AAV vectors have also been evaluated in 
phase I/II clinical trials for the treatment of Alpha-1 antitrypsin (AAT) deficiency, using an AAV1 vector 
delivered via intramuscular injections to deliver a functioning copy of the Alpha-1 antitrypsin gene155.  
Additionally, AAV gene therapies are currently being developed for treating numerous 
neurological and neurodegenerative diseases characterized by an underlying genetic component. Two of 
14 
the most predominant indications being pursued in the CNS space are for Parkinson’s disease and 
Alzheimer’s disease142. As an example, Voyager has recently developed a drug using an AAV vector to 
deliver amino acid decarboxylase to improve L-Dopa levels for the treatment of Parkinson’s, which has 
shown promising safety profiles improvement in patient motor functions following phase 1 clinical 
studies156. Similarly, gene therapies using AAV vectors could be developed to target Parkinson’s by 
delivering various other therapeutic genes to replace those identified as disease-associated mutations, 
such as those involved in lysosomal trafficking defects. Less prominent neurological diseases with a 
genetic component, such as Gauche’s disease, Pompe disease, and Canavan disease are also being 
targeted with AAV-based pipelines157–160.  
Production and Purification of Recombinant AAV Vectors. Recombinant AAV (rAAV) vectors 
were first generated in the 1980s using AAV2161. Production of rAAV vectors can be done by replacing 
the rep & cap genes with a transgene driven by a promoter of choice along with whatever regulatory 
elements desired, as long as the total size of the transgene cassette is under the 4.5 kb packaging capacity. 
This transgene cassette is inserted between the flanking ITRs, replacing the rep and cap genes of the WT 
genome. These ITRs serve as the only cis elements required for packaging. The triple plasmid 
transfection method is generally used to produce rAAV vectors. A producer cell line is used to produce 
the virus. Generally, HEK293 cells are used for this; however, alternative methods such as insect cell-
based methods (i.e. using baculovirus/sf9 cells) are also used.  
In the triple transfection method, the producer cells are transiently transfected with three 
plasmids15,141,162. The first is the aforementioned transgene packaging cassette in a TR backbone. The 
second plasmid provides the rep and cap genes of the WT AAV genome in trans to facilitate production. 
For producing rAAV in the lab, a cap gene of choice is provided alongside the AAV2 rep gene, which 
generally remains constant. The third and final plasmid provides helper genes from Ad, which are 
required to facilitate replication of the AAV genome15. These plasmids are transfected using PEI and 
virus is harvested 2-5 days post transfection, depending on the protocol. Depending on the serotypes 
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being produced, virus may be harvested from the supernatant and/or the cell pellet, depending on the 
serotype being made.  
Once produced and harvested, a variety of methods are employed to purify rAAV preps141,163–167. 
In the lab, small-scale preps are purified using PEG precipitation followed by loading onto a density 
gradient (either cesium chloride or iodixanol) and purified by ultracentrifugation. Depending on the 
serotype, sonication may be used prior to ultracentrifugation in order to isolate virus from the cells. 
Following ultracentrifugation, further purification steps such as dialysis or buffer exchange are used; 
additionally, further purification using a sucrose gradient is employed if more pure virus is needed. 
Lastly, purified virus preps may be concentrated via centrifugation using size-exclusion columns. 
Finally, purified virus preps are titered using qPCR as a gold standard (generally with primers 
specific for either the transgene or universal primers targeting the ITR) or dot blots. Subsequent 
biochemical methods can be employed as quality control, including Western blots and electron 
microscope (to assess purity and ratio of empty:full capsids, respectively). While production of small-
scale virus preps at high titer are relatively easy to perform in an academic laboratory setting, scaling up 
to large-scale good manufacturing practice (GMP) virus production is both challenging and costly. 
Various methods have been employed to improve these methods, including replacement of adherent 
HEK293 producer cells with suspension cultures, and further using larger bioreactors and cell stacks to 
process larger volumes166,168–176. Furthermore, a substantial amount of virus is lost in purification steps, 
and large-scale manufacturers are employing alternative techniques, such as tangential flow filtration and 
various forms of chromatography177–179.  
Challenges Facing AAV-Mediated Gene Therapy. Despite its success, there are still several 
obstacles to overcome for successful AAV-mediated gene therapy. First, there is the prevalence of pre-
existing neutralizing antibodies in the patient population, which range up to ~80% of the population for 
some of the more common AAV serotypes10,180,181. This may preclude patients from treatment/clinical 
trials. Both the use of less prevalent capsid serotypes (which are less likely to be recognized by pre-
existing neutralizing antibodies in the patient population) as well as the use of transient immune 
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suppression are two strategies which have shown promise in circumventing pre-existing immunity. Both 
the use of less prevalent AAV serotyped capsids and capsid engineering efforts are continually being 
pursued in order to generate AAV vectors capable of escaping pre-existing immunity while still mediating 
therapeutic expression levels 57,96,158,182–185.  
Second is the limited packaging capacity (4.5 kb) of rAAV vectors, which prevents larger 
transgenes from being eligible for AAV-mediated gene delivery. Importantly, efforts have been made 
utilizing dual AAV vectors to deliver these larger transgenes as split versions, packaged within different 
capsids, which rely on co-infection of the same cell with both vectors and subsequent recombination 
events, or similarly, dual vectors in which the transcriptional elements are delivered separately from the 
transgene186–188. These efforts have been met with limited results, but there has been some success in 
engineering smaller, minimal versions of large transgenes, such as dystrophin. For instance, a smaller 
micro dystrophin has been engineered which is small enough to be packaged and delivered using rAAV 
vectors187.  
A third obstacle facing rAAV vectors is the requirement for high dosages in order to achieve 
therapeutic expression levels of transgenes in human patients. Many gene therapy applications require 
extremely high virus titers to be administered, i.e. 2.5 x 1014 vg/kg for a recent SMA clinical trial, in order 
to achieve therapeutic transgene expression levels189. This need to administer such high vector loads can 
in order to achieve therapeutic levels of expression can result in unfortunate consequences. Firstly is the 
difficulty associated with GMP production of AAV vectors at high enough titers for clinical use in human 
patients. Production of such high viral titers is extremely difficult and results in considerable scale-up 
costs.  Innovations in production methods (i.e. suspension 293 cell systems and the use of baculovirus/sf9 
insect cell protocols) as well as purification schemes (i.e. moving from density ultracentrifugation to 
methods such as tangential flow filtration and various forms of column chromatography) are continually 
being made to improve manufacturing168,169. Secondly, administration of such high vector loads has the 
potential to result in unfortunate side effects such as dose-related hepatotoxicity, as has been seen lately 
for systemically administered AAV9-based vectors190–192. 
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This need for improved efficiency of viral vectors goes hand in hand with a need to improve the 
(tissue) specificity of vectors. Thus, there is an inherent struggle between optimizing and balancing both 
efficiency and specificity (i.e. transduction & tropism). For example, vectors that transduce cells in 
specific target tissues (i.e. the CNS) at a high level (i.e. AAV9 and AAVrh.10) also transduce peripheral 
tissues, such as the liver, at high levels112,157,193,194. When delivered systemically, these vectors suffer from 
liver sequestration. Even when these vectors are delivered directly into the CNS through 
intracerebroventricular injections, they suffer from systemic leakage, and still transduce the liver195. 
Efforts of have been made to place transgenes under the control of a cell-type specific promoter in order 
to optimize specificity, such as the human synapsin (hSyn) promoter, which expresses only in neurons; 
however, this results in a dramatic drop in transduction efficiency, compared to expression using a more 
ubiquitous promoter, such as the chicken beta actin (CBA) or CMV promoter196. Thus, this issue is 
sometimes thought of in terms of an equation in which efficiency plus specificity equals 1, where the two 
are at odds in a zero-sum game. Nonetheless, capsid engineering efforts in our lab and others, are 
continually focused on improving both efficiency and specificity of rAAV vectors, with the goal of 
achieving therapeutic expression levels at a lower dose.  
1.8. Gene Therapy for the Central Nervous System Using AAV Vectors 
CNS Gene Therapy and AAV. There has been a lot of success so far in using rAAV vectors to 
achieve therapeutic CNS gene transfer for targeting multiple neurological diseases, in both preclinical and 
clinical studies157. AAV possesses many attributes which make it an ideal vector for gene transfer to the 
CNS and there are many natural and synthetic serotypes with varied phenotypes in regards to CNS 
transduction and tropism105. Also detailed in previous sections, these attributes are largely the result of 
structural variation and differential glycan receptor usage. Gene therapy has emerged as an attractive 
means to treat numerous neurological disorders of the CNS that are characterized by an underlying 
genetic basis. Indications include examples such as Parkinson’s disease and Alzheimer’s disease. For 
example, neurodegenerative disorders such as Huntington’s disease and Parkinson’s disease, 
characterized by loss of GABAergic and dopaminergic neuron populations, respectively, can be treated 
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through gene replacement using rAAV vectors to restore cellular functions and prevent 
neurodegeneration157,159. 
Examples of CNS Gene Therapy. Additionally, CNS gene therapy is being pursued to treat 
numerous lysosomal storage disorders (LSDs) such as Krabbe disease, Gaucher disease, Pompe disease, 
and various mucopolysaccharidoses disorders (MPS)157. These diseases are often caused by loss-of-
function mutations which lead to insufficient enzymatic activities, altered metabolism and the 
accumulation of toxic products within the cell. This buildup leads to cell death and/or dysfunction, and 
the resulting neurodegeneration ultimately causes the cognitive and/or motor defects associated with the 
respective diseases197–199. Similar genetic defects resulting in altered lysosomal storage dysfunctions have 
also been implicated in causing Parkinson’s disease as well200. Similarly, gene therapy products are 
currently being developed to treat Parkinson’s disease through delivery of an amino acid decarboxylase 
(AADC) transgene to increase dopamine levels and are currently undergoing clinical trials156.  
1.9. AAV in the Brain – Phenotypes, Routes of Delivery, & Transport 
AAV Transport within the CNS. Within the CNS, AAV undergoes several modes of transport, 
which can also be affected by capsid structure/receptor usage, route of delivery, and the animal models 
used157. Once in the CNS, AAV vectors can undergo paravascular transport through the CSF and 
interstitial fluid, through the recently characterized glymphatic pathway201,202. Recently, studies from our 
lab demonstrated a role for glymphatics, and aquaporin 4-mediated water transport, in the paravascular 
clearance of AAV203. AAV spread in the CNS is known to occur via axonal transport subsequent to 
neuronal infection, where the virus can travel to other brain regions through one or both directions204. 
Anterograde transport occurs across the synapse and the virus is taken up by dendrites of the receiving 
neuron, facilitating transduction of that cell or release of the virion to transduce nearby cells. Conversely, 
retrograde transport occurs when viruses are taken up at an axon and transported back to the neural cell 
body. The direction of axonal transport, and whether it is unidirectional or bidirectional depends on the 
capsid204. For instance, AAV1 and AAV6 have both been shown to display exclusively retrograde 
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transport, while AAV2 is only transported in the anterograde direction204,205.  AAV8/9, however, can be 
transported bidirectionally206.  
Routes of administration for CNS Gene Delivery. CNS transduction is largely influenced by the 
tropism of the AAV capsid being used; however, the route of injection also plays a large role. Several 
routes of administration exist for AAV vectors targeting the CNS, both directly and indirectly, and have 
been performed in different animal models157,207,208. Direct CNS administration can be achieved through 
intraparenchymal injections directly into the brain tissue and through administering directly to the 
cerebrospinal fluid (CSF). Intra-CSF routes include intracerebroventricular (ICV), intracisternal (IC), and 
intrathecal (IT) injections into the spinal cord. Intracranial routes generally use stereotaxic injections.  
Intraparenchymal injections. Direct injections into the brain parenchyma are the most invasive 
and generally result in punctate transduction profiles. While many serotypes can effectively transduce a 
given brain region upon direct intraparenchymal injections at that site, their transduction is limited to the 
site of injection209. Generally these injections have been performed targeting specific brain regions, such 
as the thalamus, striatum, hippocampus, etc. Serotypes like AAV2, AAV4, and to a slightly lesser degree, 
AAV1 and AAV5, show limited spread in the CNS, punctate expression localized to the region injected, 
and generally show a preferentially neuronal tropism104,210. Thus intraparenchymal injections are desirable 
for applications in which highly localized and limited gene transfer is desired, but less suited for 
applications requiring more global gene transfer.  
Intra-CSF administration. Intra-CSF administration, while being similarly invasive, provides the 
ability to transduce larger areas of the brain. Nonetheless, spread of the virus away from the direct site of 
injection (i.e. the specific ventricle or cisterna magna) is variable, depending on the capsid. Intra-CSF 
administration of AAV vectors has been used to successfully achieve CNS gene transfer104,157,211. 
Intrathecal (IT) administration via lumbar puncture has proven successful as well157,184,212. AAV1/5/6/8/9 
efficiently transduce the spinal cord and brain stem following IT administration, with AAV9 
outperforming the others213,214. AAV2/4 generally show the least spread, with AAV1/5/6 generally 
showing slightly more spread and moderately higher transduction levels in the CNS. AAV8/9/rh.8/rh.10 
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have all been shown to mediate the highest transduction levels and spread more effectively in the CNS 
than other natural serotypes, following intra-CSF administration through the various routes discussed 
above105,215,216. Furthermore, AAV1/2/6 capsids mediate preferentially neuronal transduction following 
intra-CSF or intraparenchymal injections157,210. AAV5 transduces both neurons and glia at low levels 
while AAV8/9/rh.8/rh.10 transduce both cell types much more efficiently105,216. AAV4, following ICV 
administration, preferentially transduces ependymal cells, and transduces astrocytes upon 
intraparenchymal injection into the subventricular zone and rostral migratory stream (RMS)217,218. 
However, our lab recently engineered an AAV4 variant, AAV4.18, which was found to have switched 
receptor usage from O-SIA to α-2,8-polysialic acid (PSA)219. This switch resulted in improved spread in 
the CNS in addition to selective transduction of migrating neural progenitor cells in the RMS. 
Furthermore recent studies from the Song lab at UNC have demonstrated that, following direct 
microinjections in the dentate gyrus, AAV4 selectively transduces quiescent neural stem cells in this 
region of the hippocampus220. 
1.10. CNS Gene Transfer Across the Blood-Brain Barrier Using AAV Vectors 
Systemic Administration. Lastly, AAV vectors can be administered systemically via intravenous 
injections (IV). This is by far the least invasive route of administration and has the added benefit of 
promoting a more global distribution of gene transfer across the brain, rather than the more localized 
expression observed for other routes. Nevertheless, it is also one of the most difficult routes for achieving 
therapeutic transduction levels, requiring both optimal capsid selection as well as high vector 
dosages157,160. This is due to either poor specificity and/or efficiency of vectors targeting the CNS, 
resulting from tropism for peripheral tissues and sequestration within these tissues, such as the liver221. 
Effective gene delivery to the CNS is also largely prohibited by the blood-brain barrier157. 
The Blood-Brain Barrier. The blood-brain barrier (BBB) prevents large and/or hydrophilic 
molecules in circulation from entering the brain parenchyma through the vasculature. Structurally, the 
BBB is composed primarily of the tight junctions formed between endothelial cells in the brain 
vasculature222. Additional components of this neurovascular unit include pericytes and smooth muscle 
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cells which line the endothelium, astrocytic end-feet, which provide biochemical support from the brain 
tissue, and the extracellular matrix (ECM) in which these interact223. The BBB precludes entry of >98% 
of drugs from entering the brain and the vast majority of all viruses, including AAV. Several pathogenic 
viruses do possess the ability to cross the BBB and infect cells in the CNS through a few clever 
mechanisms224. For instance, HIV can hitchhike along extravasating immune cells225. Others, like Rabies, 
infect peripheral nerve cells and cross into the brain though axonal transport226. Contrarily, some 
pathogenic viruses utilize mechanisms which disrupt the integrity of the BBB in order to gain entry into 
the CNS, such as the induction of hemorrhages by mouse adenovirus227.  
AAV & the BBB. As a very simple virus with a limited coding capacity, both wildtype AAV as 
well as rAAV vectors are unable to use the more complicated mechanisms employed by pathogenic 
viruses, as discussed above. Thus, most AAV serotypes are unable to cross the BBB and enter the brain 
parenchyma following systemic administration. This includes most of the common serotypes (i.e. AAV1-
6 and AAV8)98. As an example, AAV1, one of the strains most relevant to this dissertation, effectively 
transduces and is sequestered within the brain microvasculature following intravenous injection. In the 
past, strategies have been employed to circumvent the BBB, such as administering vectors in preclinical 
animal models with a seizure-compromised BBB or through the use of drugs (i.e. mannitol) to disrupt the 
BBB228,229. 
Notably, several of the more recently discovered serotypes, many of which were isolated from 
nonhuman primates, effectively cross the intact BBB following systemic administration and transduce 
cells within the brain parenchyma98. These neurotropic capsids include AAV7, AAV9, AAVrh.8, 
AAVrh.10, AAVrh.39, and AAVrh.43, and have further expanded the vector toolkit. In a direct 
comparison following facial vein injections in neonatal mice, AAV9, AAVrh.8, and AAVrh.10 were 
found to exhibit the highest CNS transduction levels. Nonetheless, they all mediated widespread CNS 
gene transfer. Of these three “top tier” capsids, AAVrh.10 and AAVrh.8 both outperformed AAV9, in 
terms of CNS transduction levels. This is noteworthy, as AAV9 is currently regarded as the gold-standard 
for CNS-targeted gene therapy. In a follow-up study by the same lab, AAV9, AAVrh.8 and AAVrh.10 
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underwent a direct head-to-head comparison evaluating CNS transduction following systemic 
administration in adult marmosets230. Here, all three exhibited high transduction levels compared to other 
serotypes, but AAVrh.8 outperformed both AAV9 and AAVrh.10.  
1.11. Engineering AAV Capsids for Gene Transfer to the Brain 
Significant efforts in recent years have focused on engineering the AAV capsid in order to 
achieve improved transduction and tropism for tissues of interest, including the CNS. Strategies to 
engineer the AAV capsid include peptide insertion, chemical conjugation and mutagenesis231–233. 
Combinatorial library-based approaches have seen increased use in recent years to generate new synthetic 
variants. Often, such libraries are created using either DNA shuffling to recombine cap genes of different 
serotypes or through targeted mutagenesis strategies228,234. Subsequently, such libraries generally undergo 
either simple screening or directed evolution in order to identify optimal capsids for the phenotype of 
interest235–237. An example of a simple screen, from our lab, is the generation of liver-detargeted AAV9 
capsid mutants238. Additionally, engraftment of structural features from one capsid to another can 
generate variants with novel phenotypes. For example, engraftment of the galactose receptor footprint 
from AAV9 onto the AAV2 capsid generated the AAV2g9 variant, which demonstrated improved 
neuronal transduction, increased spread, and reduced systemic leakage following ICV injections239. Our 
lab has recently developed a structure-guided evolution platform, utilizing random mutagenesis of 
specific capsid regions, informed by structure-function studies, and targeted evolution to generate AAV 
variants for immune invasion while retaining tropism and transduction properties182. This platform can be 
extended to carry out structure-guided evolution of glycan receptor footprints as well, which is the focus 
of future studies.  
Capsid strategies such as these have been employed and are continually iterated upon in order to 
expand the vector toolkit for improving CNS gene transfer. In particular, many efforts have been made to 
generate capsid variants with improved CNS gene transfer following systemic administration, to expand 
upon the aforementioned naturally neurotropic isolates. These generally involve library-based strategies 
including directed evolution and screening for CNS gene transfer following systemic administration. For 
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example, directed evolution of capsid libraries has generated a couple capsid variants which are able to 
cross the seizure-compromised BBB; however, these are unlikely to cross an intact BBB228. A similar 
approach was used to generate the synthetic AAV-B1 capsid, which showed improved transduction of the 
motor cortex and thalamus, as well as the spinal cord, relative to AAV9 following IV injection240. Similar 
region-focused improvements in gene transfer were observed for the synthetic AAV-AS variant, 
generated through peptide-display241. The AAV2-retro vector was engineered through a combination of 
peptide display and directed evolution and generated a vector with a strong propensity for retrograde 
axonal transport242. Recently, a Cre recombinase-based AAV targeted evolution (CREATE) method was 
developed to generate capsids with improved transduction of specific cellular populations in the CNS 
after IV injections in mice243. This method employed evolution of a peptide-insertion motif inserted into 
the C-terminus of the AAV9 VP3, and resulted in generation of the AAV-PHP.B vector. AAV-PHP-b 
was found to improve gene transfer to the astrocytes and neurons in the brain by 40-fold relative to 
AAV9. Subsequent iterations of this method generated further improved capsids, AAV-PHP.eB and 
AAV-PHP.S, which exhibit vast improvements relative to AAV9 in terms of CNS and peripheral nervous 
systems, respectively, following IV injection244. While the AAV-PHP capsids have garnered a lot of 
attention due to their extremely robust CNS transduction profile, recent studies have shown that these 
CNS transduction properties are limited to the C57BL/6J mouse background upon which they were 
selected, and that they fail to transduce BALB/cJ or nonhuman primates245.  
This dissertation highlights the efforts I have made towards furthering our understanding of AAV 
biology in regards to neurovascular transport and CNS tropism/transduction following systemic 
administration. In Chapter 2, I set out to dissect the structure-function correlates for the transport of AAV 
across the BBB. Subsequently, in Chapter 3, I expand upon this by attempting to dissect the role of 
capsid-sialic acid interactions on BBB traversal and CNS transduction. 
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Figure 1.1. Structure of the AAV Viral Protein monomer. Cartoon diagram of the AAV1 VP3 (PDB 
ID # 3NG9) monomer. The monomer has a β-barrel jellyroll structure with 8 antiparallel β-sheets (βB-βI, 
indicated as arrows on the diagram) and a single α helix (αA). This diagram depicts the variable regions 
(VR) I-IX which are located on surface-exposed loops connecting the various β-strands, and are critical 
determinants for tropism antigenicity and receptor usage. The variable regions are color-coded as follows: 
VR-I is red, VR-II is orange, VR-III is yellow, VR-IV is light green, VR-V is dark green, VR-VI is teal, 
VR-VII is blue, VR-VIII is purple, VR-IX is magenta, and the HI loop is brown.  
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Figure 1.2. AAV capsid structure and axes of symmetry. Surface-rendered homology models 
generated in PyMoL showing the full T=1 icosahedral 60mer AAV1 capsid (PDB ID # 3NG9, left) 
alongside the various axes of symmetry – the two-fold axis of symmetry (i.e. VP3 trimer dimer, top), 
five-fold axis of symmetry (VP3 pentamer, middle), and the three-fold axis of symmetry (i.e. VP3 trimer, 
bottom). 
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CHAPTER 2: MAPPING THE STRUCTURAL DETERMINANTS REQUIRED FOR AAVRH.10 
TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER1 
2.1. Overview 
Effective gene delivery to the central nervous system (CNS) by intravenously administered 
adeno-associated viral (AAV) vectors requires crossing the blood-brain barrier (BBB). In order to achieve 
therapeutic CNS transgene expression, high systemic vector doses are often required which pose 
challenges such as scale up costs and dose-dependent hepatotoxicity. In order to improve the specificity 
and efficiency of CNS gene transfer, a better understanding of the structural features that enable AAV 
transit across the BBB is needed. We generated a combinatorial domain swap library using AAV1, a 
serotype that does not traverse the vasculature, and AAVrh.10, which crosses the BBB in mice. We then 
screened individual variants by phylogenetic and structural analyses and subsequently conducted systemic 
characterization in mice. Using this approach, we identified key clusters of residues on the AAVrh.10 
capsid that enabled transport across the brain vasculature and widespread neuronal transduction in mice. 
Through rational design, we mapped a minimal footprint from AAVrh.10, which, when grafted onto 
AAV1, confers the aforementioned CNS phenotype, while diminishing vascular and hepatic transduction 
through an unknown mechanism. Functional mapping of this capsid surface footprint provides a roadmap 
for engineering synthetic AAV capsids for efficient CNS gene transfer with an improved safety profile.  
                                                          
 
1This chapter previously appeared as an article published in the journal Molecular Therapy and is reprinted 
with permission with some modifications. The original citation is as follows: Albright BH, Storey CM, 
Murlidharan G, Castellanos Rivera RM, Berry GE, Madigan VJ, Asokan A. Mapping the Structural 
Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier. Molecular Therapy 26: 
510-523, 2018. 
27 
2.2. Introduction 
Adeno-associated viruses (AAV) are non-pathogenic parvoviruses composed of a small, 25 nm 
icosahedral capsid packaging an approximately 4.7 kb single-stranded DNA genome55. A wide array of 
AAV capsid sequences have been isolated from human and primate tissues, which have been categorized 
into several distinct clades based upon sequence and structural diversity246,247. Across these clades, 
different serotypes display broad tropism at the species, tissue and cellular levels19,246,247. These diverse 
phenotypes are determined by capsid structure19. The AAV capsid is assembled from 60 viral protein 
(VP) subunits. The core VP monomer (VP3) has a jellyroll, beta barrel structure comprised of 7 anti-
parallel beta strands connected by interdigitating loop regions. Portions of these highly variable loops are 
surface exposed and define the topology of the AAV capsid, which in turn determines tissue tropism, 
antigenicity and receptor usage across the various AAV serotypes19. The surface loop residues on the 
AAV capsid are highly plastic and amenable to modification, affording control over antigenicity, 
transduction profile and tissue tropism248.  
The first step in the AAV lifecycle is recognition of and attachment to cell surface glycan 
receptors19. These include heparan sulfate (HS) for AAV2, AAV3 and AAV6, α2,3- and α2,6- N-linked 
Sialic acid (SIA) for AAV1, AAV5 and AAV6, O-linked sialic acid for AAV4, and galactose (Gal) for 
AAV956. Secondary to glycan binding, cellular uptake of AAV implicates secondary co-receptors, 
including various growth factor receptors as well as integrins40,42,44,249. Recently, a transmembrane protein, 
KIAA0319L (AAVR) has been identified as a universal receptor for multiple AAV serotypes250. These 
factors, along with tissue glycosylation patterns, contribute to the varying tissue tropisms of different 
AAV serotypes. Particularly with regard to the CNS, different AAV serotypes display a spectrum of 
transduction profiles and cellular tropisms, depending on the route of administration157. For example, 
when directly administered into the mouse CNS through either direct intra-parenchymal or intra-
cerebrospinal fluid (CSF) injections, AAV capsids undergo axonal transport and transynaptic spread in 
the anterograde and/or retrograde directions, depending on the serotype157. Furthermore, our lab has 
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recently shown that glial-associated lymphatic (glymphatic) transport of CSF influences AAV spread 
within the mouse brain parenchyma and clearance from the CNS203.  
 To achieve CNS gene transfer, intravenously administered AAV vectors must first cross the 
blood-brain barrier (BBB) in order to gain entry into the brain. Comprised of endothelial cell tight 
junctions along with associated astrocytic end-feet and pericytes, the BBB blocks the diffusion and 
paracellular flux of macromolecules/particles and regulates the transport of other molecules251. Most 
viruses which infect the brain do so through disrupting or weakening the BBB; however, some viruses 
have devised strategies to gain entry into the CNS by methods such as hitchhiking within host immune 
cells (HIV), by infecting brain endothelial cells or by infecting peripheral nerves and exploiting axonal 
transport (e.g., Rabies)252,253. In the case of AAV, the BBB prevents entry of most serotypes into the brain 
with a few notable exceptions. For instance, intravascular administration of AAV serotypes 1-6 and 8 
results in poor CNS transduction, while isolates AAV9, AAVrh.8 and AAVrh.10 have been shown, 
amongst others, to efficiently traverse the BBB in different animal models254–257. In the current study, we 
generated a chimeric capsid library by shuffling the Cap genes of two isolates, AAV1 and AAVrh.10, 
which, despite a high degree of structural similarity, display distinct CNS phenotypes. While AAV1 does 
not appear to cross the BBB efficiently and predominantly transduces the brain endothelium, AAVrh.10 
transduces the brain parenchyma by crossing the murine and non-human primate BBB254,258. Using a 
combination of structural analyses and bioinformatics followed by in vivo screening, we identified a 
structural footprint on the AAVrh.10 capsid which, when grafted onto AAV1, imparts the ability to 
traverse the BBB and preferentially transduce neurons within the brain parenchyma.  
2.3. Methods 
Generation of a chimeric AAV capsid panel. An AAV1/rh.10 domain swap capsid library was 
generated through DNA shuffling. Briefly, the Cap genes of AAV1 and AAVrh.10 were randomly 
fragmented by brief DNase digestion and reassembled using primerless PCR with Phusion High-Fidelity 
DNA polymerase (NEB Cat #M0530L) in which the partial homology of the short (< 400 bp) fragments 
allows for self-priming of the fragments. A secondary PCR step using specific conserved primers flanking 
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the Cap gene were then used to amplify the library of reassembled full-length Cap sequences and 
simultaneously insert flanking restriction sites to facilitate subsequent cloning into a pTR plasmid 
backbone used for virus production. 
Phylogenetic and sequence analyses. The amino acid sequences of different AAV capsid isolates 
were aligned using ClustalW and phylogenetic trees were generated using the MEGAv7.0.21 software 
package259. The phylogeny was produced using the neighbor-joining algorithm and amino acid distances 
were calculated using a Poisson correction260. Statistical testing was done by bootstrapping with 1,000 
replicates to test the confidence of the phylogenetic analysis and to generate the bootstrap consensus 
tree261. Branches corresponding to partitions reproduced in less than 50% of bootstrap replicates are 
collapsed. The percentage of replicate trees in which associated taxa clustered together in the bootstrap 
test is displayed next to the branches. All sequence alignments were performed using Invitrogen’s Vector 
NTI Advance 11.5.2 software.  
Virus production and titers. An updated triple plasmid transfection protocol was used to produce 
recombinant AAV vectors195. Specifically, the transfected plasmids include (i) a capsid-specific pXR 
helper plasmid (i.e. pXR1, pXRrh.10, or various plasmids encoding the various chimeric Cap genes used 
in this study), (ii) the adenoviral helper plasmid pXX680, and (iii) either pTR-CBh-scGFP or pTR-CBA-
Luc plasmids (encoding either a self-complementary green fluorescent protein (GFP) reporter transgene 
driven by the chicken beta actin hybrid (CBh) promoter or a luciferase reporter transgene (Luc) driven by 
the chicken beta actin promoter (CBA), respectively, flanked by inverted terminal repeats (TRs) derived 
from the AAV2 genome. Viral vectors were purified using iodixanol density gradient ultracentrifugation. 
Vectors packaging a CBh-scGFP transgene were subsequently subjected to buffer exchange and 
concentration using Sartorius Vivaspin2 100 kDa molecular weight cut-off (MWCO) centrifugation 
columns (F-2731-100 Bioexpress, Kaysville, UT). Vectors packaging a CBA-Luc transgene were 
subjected to buffer exchange and de-salting using Zeba Spin Desalting Columns, 40K MWCO (Thermo 
Scientific, Cat # 87770). Following purification, viral genome titers were determined via quantitative 
PCR using a Roche Lightcycler 480 (Roche Applied Sciences, Pleasanton, CA). Quantitative PCR 
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primers were designed to specifically recognize the AAV2 inverted terminal repeats (forward, 5’- 
AACATGCTACGCAGAGAGGGAGTGG –3’; reverse, 5’- 
CATGAGACAAGGAACCCCTAGTGATGGAG -3’) (IDT Technologies, Ames IA).  
Animal studies.  All animal experiments were performed using 6-to-8-week-old female C57/BL6 
mice purchased from Jackson Laboratories (BAR Harbor, ME). These mice were maintained and treated 
in compliance with NIH guidelines and as approved by the UNC Institutional Animal Care and Use 
Committee (IACUC).  To investigate the ability of AAV vectors to cross the BBB and transduce CNS 
cell populations, AAV vectors packaging a CBh-scGFP transgene or 1x PBS (as mock treatment) were 
administered intravenously (i.v.) via tail vein injection at a dose of 5 x 1011 vg. To assay for GFP reporter 
transgene expression, animals were sacrificed 21 days post injection with tribromoethanol (Avertin) (0.2 
ml of 1.25% solution) followed by transcardial perfusion with 30 ml of 1x PBS followed by 30 ml of 4% 
paraformaldehyde in PBS. Tissues including the brain, heart and liver were removed and post fixed for 24 
h, and 50-μm-thick sections were obtained for each tissue using a Leica VT 1200S vibrating blade 
microtome (Leica Biosystems, IL). The mouse brain sections were then immunostained as described 
below. For in vivo luciferase transduction and viral genome biodistribution experiments, mice were 
injected with either 1x PBS or viral vectors packaging a CBA-Luciferase transgene at a dose of 1 x 1011 
vg. Mice were sacrificed, as described above, at 14 days post injection and various tissues were removed. 
For these experiments, no fixation with 4% paraformaldehyde in 1x PBS was performed and instead 
tissues were dissected and frozen at -80⁰C prior to use.  
To quantify luciferase expression, mice injected with 1 x 1011 viral genomes packaging a CBA-
Luc transgene were sacrificed at 14 days post injection and tissues were harvested and frozen at -80 ⁰C. 
Tissues were later thawed, weighed and lysed by adding 150 μl of 2x passive lysis buffer (Promega, 
Madison WI) prior to mechanical lysis using a Tissue Lyser II 352 instrument (Qiagen, Valencia, CA) 
followed by centrifugation to remove any remaining tissue debris. To measure luciferase transgene 
expression, 50 μl of supernatant from each lysate was then loaded onto an assay plate along with 50 μl of 
luciferin and luminometric analysis was performed using a Victor2 luminometer (PerkinElmer, Waltham, 
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MA). The relative light units obtained for each sample were then normalized to the input tissue weight for 
each sample, measured in grams. Data was graphed and statistical analyses carried out using an unpaired 
two-tailed T-test with Welch’s correction as well as ANOVA followed by Tukey’s multiple comparisons 
test where indicated. These statistical analyses were performed in GraphPad Prism 6® software. 
Tissue processing and histological analysis. For mouse experiments using virus packaging a GFP 
reporter transgene, free-floating 50-μm-thick coronal brain sections were stained in 24-well plates. 
Sections were incubated in blocking buffer containing 10% goat serum and 1% Triton X (Sigma-Aldrich) 
in 1x PBS for 1 hour at room temperature. The sections were then incubated at 4⁰C overnight with a 
primary monoclonal rabbit α-GFP antibody (Life-Technologies-G10, 362 1:750) diluted in blocking 
buffer. The next day, three 10 minute washes were performed with 1x PBS. The subsequent histochemical 
analysis of GFP expression was performed using a Vectastain ABC kit (Rabbit IgG PK-4001 kit, Vector 
biolabs, Burlingame, CA) and tissues were mounted onto microscopy slides. The immunostained sections 
were digitally imaged in brightfield (20x objective) using an Aperio ScanScope XT instrument (Aperio 
Technologies, Vista, CA) by the UNC Translational Pathology Laboratory and images were obtained 
using Leica eSlide Manager (centralized image storage and data management software) and analyzed 
using Aperio ImageScope and WebViewer software. Quantifications were calculated by counting the 
number of GFP+ neuronal or glial cells, determined based upon morphology, per 50 μm coronal brain 
section. Data was graphed and statistical analyses were performed as outlined above. Specific brain 
regions were identified based upon comparison to a coronal mouse brain reference obtained from the 
Allen Mouse Brain Atlas262.  To assay for GFP expression in the heart and liver, tissues were stained for 
GFP with the anti-GFP primary antibody as described above; however, an anti-rabbit goat antibody 
conjugated to Alexa-488 was used as the secondary antibody at a dilution of 1:500 (anti-rabbit Abcam-
96,883). Immunostained GFP in these tissues was then imaged using an EVOS FL epifluorescence cell 
imaging system (AMC/Life Technologies) using the GFP light cube (excitation 470 nm, emission 510 
nm). Statistical analyses were carried out as outlined earlier.  
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Vector genome biodistribution. Animal studies were performed as described above. At 21 days 
post injection, mice were sacrificed and tissues were frozen at -80⁰C. Tissues were later thawed and viral 
genomes were extracted from the tissue lysates using the DNeasy kit (Qiagen, Valencia, CA). Viral 
genome copy numbers were then determined for each tissue using quantitative PCR with primers specific 
to the luciferase transgene (forward, 5′- AAAAGCACTCTGATTGACAAATAC -3′; and reverse, 5′- 
CCTTCGCTTCAAAAAATGGAAC -3′). These viral genome copy numbers were then normalized to the 
mouse lamin B2 housekeeping gene using the primers (forward, 5′- 
GGACCCAAGGACTACCTCAAGGG -3′; and reverse, 5′- AGGGCACCTCCATCTCGGAAAC -3′). 
The biodistribution of viral genomes are represented as the ratio of vector genomes per cell recovered for 
each tissue. Data was graphed and statistical analyses carried out as described earlier.  
Molecular modeling. Previously published coordinates (PDB ID, 3NG9) were used to generate 
three-dimensional structures of the AAV1 VP3 trimer/three-fold axis of symmetry.263 Homology models 
of AAVrh.10 and various AAV1/rh.10 chimeric capsid structures were obtained using the SWISS-Model 
server (http://swissmodel.expasy.org/)264, with the crystal structure of AAV8 VP3 (PDB ID, 2QA0) used 
as a template and a structure-based alignment was generated using the secondary structure matching 
(SSM) application in the WinCoot software59,205,265, with the AAV1 VP3 (PDB ID 3NG9) monomer being 
used as a template. The VP3 trimers/3-fold symmetry axes, VP3 trimer dimers/2-fold symmetry axes, 
VP3 pentamers/5-fold symmetry axes, and full capsids were generated using the VIPERdb oligomer 
generator utility (http://viperdb.scripps.edu/oligomer_multi.php)266. Surface rendered depictions of these 
models were visualized using PyMOL (the PyMOL Molecular Graphics System, Schrödinger LLC, 
http://www.pymol.org/). Stereographic roadmap projections of the AAV1RX capsid surface highlighting 
surface-exposed amino acid residues within the AAVrh.10-derived neurotropic footprint were generated 
using RIVEM (Radial Interpretation of Viral Electron Density Maps) software267. 
2.4. Results 
 Generation of an AAV1/rh.10 domain swap library and isolation of chimeric capsid variants. We 
hypothesized that the comparative analysis of different capsid domains will allow us to ascertain 
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structure-function correlates for traversing the BBB. Correspondingly, we generated an AAV1/rh.10 
domain swap library through DNA shuffling. We selected AAV1 and AAVrh.10 as parental capsid 
sequences for DNA shuffling since they differ markedly in their abilities to cross the BBB and because of 
the sequence homology (85%) shared by their capsid (Cap) genes. Thirty-six chimeric capsid sequences 
were then clonally isolated and sequenced. The variants generated from this library displayed substantial 
diversity at the DNA and amino acid level. Sequence alignment revealed a spectrum of domain swaps, 
which we then organized in order of increasing homology from AAV1 to AAVrh.10 (Fig. 2.1c), top to 
bottom). This panel of clones was further characterized phylogenetically by constructing a neighbor-
joining tree, which broadly categorized these variants as either more AAV1-like (Clade A) or more 
AAVrh.10-like (Clade E) (Fig. 2.1b). Small-scale vector production was then used to establish relative 
titers to exclude capsids defective in assembly or packaging from the study. Homology-based structural 
models of the parental and representative chimeric capsid trimers highlighting key surface 
domains/residues at the three-fold axis of symmetry (Fig. 2.1c) were generated to further narrow the list 
of chimeric capsid variants for initial screening in vivo. Ten chimeric capsid variants were selected based 
on structural analyses, out of which six yielded recombinant vectors (packaging scGFP or ssLuc 
transgene cassettes) at titers similar to parental AAV1 and AAVrh.10 vectors. These variants were then 
screened further.  
In vivo screening identifies two AAV1/rh.10 chimeric capsids capable of crossing the BBB after 
intravenous administration in adult mice. We hypothesized that, based on their structural diversity, the 
selected panel of capsid variants would differ in their ability to cross the BBB and transduce the CNS 
after I.V. administration. It is important to note that our approach does not involve directed evolution, as 
this strategy is generally applicable for selecting optimal capsids and less suited for studying structure-
function relationships. We injected 6-8-week-old mice with a dose of 5 x 1011 viral genomes (vg) per 
mouse of AAV1, AAVrh.10, or one of six different chimeric AAV vectors packaging a self-
complementary CBh-GFP reporter cassette via tail vein injection. Immunostaining of coronal brain 
sections at three weeks post-injection revealed that AAV1 transduction in the cerebral cortex was limited 
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to the vasculature while AAVrh.10 demonstrated robust transduction of various cell populations, 
including neurons, glia and endothelial cells, as determined morphologically (Fig. 2.2). Further 
morphological assessment of GFP+ cells indicates differing phenotypes for the chimeric variants. 
AAV1R19.1 and AAV1R20 transduce predominantly microvascular endothelial cells in the cortex, while 
low to modest transduction of neuronal and glial cells is evident for AAV1R8 and AAV1R19d vectors 
(Fig. 2.2). In contrast, AAV1R6 and AAV1R7 demonstrate robust transduction of cortical neurons with 
modest transduction of glia and scarce, if any, transduction of the vasculature within the cortex. 
Representative images of the somatosensory area of the cortex at high magnification are shown. A similar 
trend for these chimeras was observed consistently across other regions of the brain (Fig. 2.3). These 
observations indicate that the chimeric capsids AAV1R6 and AAV1R7 likely possess the ability to cross 
the BBB, similar to the parental AAVrh.10 vector, although the mechanism is unknown. However, unlike 
either parent, AAV1 or AAVrh.10, neither chimera efficiently transduces the vasculature.  
Intravenously delivered AAV1R6 and AAV1R7 chimeric capsids cross the BBB and transduce 
neurons preferentially throughout the brain. Having identified the AAV1R6 and AAV1R7 chimeras as 
variants able to cross the BBB and transduce the CNS following systemic injection, we next sought to 
further characterize the transduction profiles of these variants across multiple functionally relevant 
structures of the brain. For each of the brain regions discussed below, representative images at higher 
magnification were obtained from mouse brain coronal sections immunostained for GFP and scanned in 
bright field at 20x magnification. Additionally, quantitative data for neuronal and glial transduction for 
each region were determined by counting GFP+ neuronal and glial cells, respectively, based on cellular 
morphology.  
Cerebral Cortex. Previous studies in mice have established that AAVrh.10 displays robust 
transduction of neuronal, glial and vascular endothelial cells throughout the cortex254. In the case of 
intravascularly delivered AAV1, vascular transduction accompanied by the absence of neuronal 
expression and low expression levels in glia has been reported257. Our analyses are consistent with these 
prior reports (Figs. 2.4 and 2.5). We also observed that intravenously administered AAV1R6 and 
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AAV1R7 (AAV1R6/7) vectors mediate robust GFP expression in cortical neurons and reduced 
expression in glia throughout the amygdalar, piriform, entorhinal, temporal association, auditory, 
somatosensory, motor, posterior parietal and retrosplenial areas of the cortex at varied yet consistently 
trending levels across the sections analyzed. Representative images of cortical regions transduced are 
shown for the motor cortex (Fig. 2.4a) and the somatosensory area of the cortex (Fig. 2.4b). Furthermore, 
AAV1R6/7 seem to display a preferentially neuronal cellular tropism across the entire cortex, showing 
moderate glial transduction and remarkably reduced vascular transduction. This profile is in stark contrast 
to the vasculotropic AAV1 as well as AAVrh.10, which transduces neuronal, glial, and vascular 
endothelial cells with high efficiency (Fig. 2.4a and 2.4b). While AAV1R6/7 mediate robust neuronal and 
moderate glial expression throughout the cortex, their expression levels are nonetheless lower than those 
achieved by AAVrh.10. These trends are corroborated by quantitation of our morphological analysis of 
GFP+ cells (Figs. 2.5a and 2.5b.), which show a statistically significant difference in cortical transduction 
relative to AAV1 for AAVrh.10, AAV1R6 and AAV1R7. One last difference to note is that AAVrh.10 
transduction across the cortex has a tendency to be concentrated at the peripheries of the tissue, around 
cortical layers 1-3, particularly within the retrosplenial, motor, somatosensory and visual cortical areas. 
While this can be attributed to differential immunostaining, we observed this phenomenon with high 
consistency across the stained AAVrh.10 sections in our analysis. This trend does not hold true for 
AAV1R6/7, which appear to mediate more uniformly distributed expression across the cortical layers.  
Hippocampus. Following intravenous delivery, the chimeric AAV1R6/7 vectors appear to 
mediate robust GFP expression in neurons throughout the hippocampus, bilaterally across brain 
hemispheres. GFP+ hippocampal neurons are observed within the CA1, CA2 and CA3 pyramidal layers 
(Fig. 2.4c, CA2 and partial CA1 shown). AAV1R6/7 also appear to be effective at transducing neurons 
within the dentate gyrus, showing a large number of GFP+ neurons which appear to be granular cells 
based on morphology (Fig. 2.4d). The neuronal transduction profile displayed by AAV1R6/7 in the 
hippocampus is similar to that seen for AAVrh.10. In contrast to AAVrh.10, however, AAV1R6/7 do not 
appear to transduce either glia or endothelial cells in either region at any appreciable level, with no 
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significant difference in GFP+ glial cells observed between AAV1 and AAV1R6/7 (Fig. 2.5c and 2.5d).  
AAV1 transduction observed in the hippocampus is again limited to the vasculature. Furthermore, these 
qualitative trends are corroborated by quantitative data for neuronal and glial cell transduction in the 
hippocampus (Fig. 2.5c) and dentate gyrus (Fig. 2.5d).  
Thalamus. GFP+ neurons were detected in the thalamus for AAV1R6/7 at levels comparable to 
AAVrh.10 (Fig. 3e). Furthermore, AAV1R6/7 demonstrate minimal transduction of the endothelium and 
dramatically reduced levels of glial transduction in the thalamus compared to AAVrh.10. These trends are 
further corroborated by quantitative data (Fig. 2.5e) in which transduction of thalamic neurons was found 
to be significantly different for AAVrh.10, AAV1R6 and 1R7, relative to AAV1. Contrarily, no 
significant difference was found for thalamic glial transduction for AAV1R6/7 relative to AAV1.   
Hypothalamus. Although somewhat variable, we observed consistently low levels of GFP 
expression, regardless of cell type, within the hypothalamus for parental and chimeric vectors when 
administered systemically (Fig. 2.4f). Variation in neuronal transduction levels in the hypothalamus was 
observed for AAVrh.10, revealing high as well as low numbers of GFP+ neurons across mice. This 
transduction profile is illustrated by the deviation shown for AAVrh.10 transduction in our quantitative 
data (Fig. 2.5f). AAV1 displays moderate hypothalamic transduction that is restricted to the vasculature. 
AAV1R6/7 vectors demonstrate low numbers of GFP+ neurons and glial cells in the hypothalamus, and a 
small number of GFP+ endothelial cells (Fig. 2.4f and Fig. 2.5f).  
Striatum. AAV1R6/7 transduce neurons in the striatum (specifically, the caudate putamen) as 
efficiently as AAVrh.10 (Fig. 2.4g), as corroborated further by our quantitative data demonstrating a 
significant difference for each relative to AAV1; however, these vectors transduce ~2-fold fewer glial 
cells and lower numbers of endothelial cells in the striatum (Fig. 2.5g) despite some observed variation.  
Amygdala. The amygdalar transduction profiles for AAV1R6/7 show robust neuronal GFP 
expression, significantly different compared to AAV1. Few GFP+ glial cells were detected, which were 
not significantly different compared to AAV1 (Fig. 2.4h and Fig. 2.5h), and barely detectable GFP+ 
endothelial cells were observed, similarly to other brain regions such as the striatum and thalamus.  
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Taken together, the morphological assessment of immunostained brain regions derived from mice 
following intravenous delivery of AAV1R6 and AAV1R7 demonstrates robust and selective neuronal 
transduction comparable to parental AAVrh.10. Furthermore, these chimeras display reduced glial 
transduction and their ability to transduce endothelial cells of the brain microvasculature appears 
diminished. Furthermore, these results appear to be consistent across various brain regions, with the 
exception of the hypothalamus, where low transduction levels in general are observed.  
AAV1R6 and AAV1R7 are de-targeted from the liver while retaining parental cardiac 
transduction profiles. Since, AAVrh.10 transduces multiple tissues, including the heart and liver, 
following systemic administration254, we analyzed the relative cardiac and liver transduction of these 
variants compared to parental serotypes by immunostaining cardiac and liver sections (Fig. 2.6a and 
2.6b). GFP expression was then quantified by averaging relative fluorescence for multiple images per 
mouse using ImageJ software (Fig. 2.6). Both chimeric vectors demonstrate comparable levels of GFP 
expression in the heart relative to the parental serotypes, AAV1 and AAVrh.10, with no significant 
difference found for AAVrh.10, AAV1R6 or AAV1R7, relative to AAV1; however, AAVrh.10 
expression levels in cardiac tissue showed substantial variation across mice (Fig. 2.6a and 2.6b). In the 
liver, AAV1 demonstrated moderate transduction levels while AAVrh.10 performed exceptionally well, 
demonstrating a log-fold higher transduction. In contrast, AAV1R6 and AAV1R7 mediated negligible 
GFP expression in the liver at background levels comparable to mock-treated mice (Fig. 2.6b) that were 
significantly reduced relative to AAVrh.10. Thus, we conclude that AAV1R6 and AAV1R7 are liver-de-
targeted relative to their parental serotypes.  
Structural analysis of the AAV1R6 chimeric capsid identifies three potential domains from 
AAVrh.10 that might enable crossing the BBB. Sequence analyses revealed that AAV1R6 is 97-98% 
identical to AAV1 with 18 unique amino acid residues derived from AAVrh.10. AAV1R7 is also largely 
identical to AAV1, but with a total of 22 AAVrh.10-derived residues, including the 18 present in 
AAV1R6. Of the 4 additional residues unique to AAV1R7, two are located within the VP1 unique 
(VP1u) N-terminal region (189I, 206A) and the other two are located at the buried VP3 N-terminal region 
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(224S and 225S). Since these residues are not exposed on the capsid surface and since the in vivo data 
suggests that the transduction profiles displayed by AAV1R6 and AAV1R7 are equivalent (Figs. 2.4 and 
2.5), we excluded AAV1R7 from the remainder of our analyses and focused on AAV1R6 alone.  
AAV1R6 possesses 3 stretches of non-consecutive residues derived from the AAVrh.10 parental 
strain. The first group of residues (group i) includes three amino acids (148P, 152R and 153S) within the 
VP1u region (Fig. 2.7a). Specifically, one residue is located adjacent to basic region 1 (BR1), which 
contains the first nuclear localization signal (NLS) of VP148,54. Additionally, group i contains two residues 
(158T and 163K) also near the NLS located within the VP2 N-terminal region (Fig. 2.7a) As mentioned 
earlier, these residues are not surface-exposed and instead remain internalized within the capsid until later 
in the intracellular trafficking pathway54.  
 The second group of AAVrh.10-derived residues on AAV1R6 (group ii) consists of 8 amino 
acids comprising the BC loop, located within variable region I (VR-I) (Fig. 2.7a and 2.7b). This region 
has previously been implicated as being important in determining the tropism and antigenicity of 
AAV1147,268. These residues are exposed on the surface of the capsid at the base of the protrusions at the 
3-fold axis of symmetry (Fig. 2.7d and 2.7f) and are also localized to the depression at the 2-fold 
symmetry axis (Fig. 2.7c and 2.7f). It is also important to note that this group of amino acid residues on 
AAVrh.10 is substituted with AAV1 residues in the chimeric AAV1R8/19/20 capsids that are unable to 
penetrate the CNS after systemic administration.   
The third group of AAVrh.10-derived residues present in AAV1R6 (group iii) includes a total of 
6 amino acids. Four of these residues (328Q, 330E, 332T and 333K) are located at VR-II, within the DE 
loop, which contributes to formation of the pore at the 5-fold axis of symmetry (Fig. 2.7a-b and 2.7e-f). 
This region on the capsid is important for viral genome packaging and release76. The last two remaining 
residues within this group (343I and 347T) are located within β-strand E, positioned within the interior of 
the capsid (Fig. 2.7a and 2.7b). Although these residues differ between AAV1 and AAVrh.10, it should 
be noted that they are relatively conserved across different AAV serotypes.  
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Rational design of AAV1RX, a chimeric capsid with a minimal footprint from AAVrh.10 for 
crossing the BBB. Using a rational approach, we narrowed down the minimum number of AAVrh.10-
derived amino acid residues in the 1R6 footprint that enable crossing the BBB and impart CNS tropism. 
We first excluded any amino acids that were not exposed on the capsid surface, eliminating stretches of 
residues located within the VP1/2 N-terminal regions of the capsid sequence (148P, 152R, 153S, 158T 
and 163K). Using the same rationale, we also excluded residues within the conserved β-strand E (343I 
and 347T) as well as those residing within VR-II, which is the pore-forming loop connecting β-strands D 
and E (328Q, 330E, 332T and 333K). Through this approach, the footprint containing 8 amino acids 
(263N, 264G, 265T, 266S, 268G (an insertion relative to the AAV1 sequence), 269S, 270T and 274T) 
found within VR-I, the loop bridging β-strands B and C, on AAV1R6 was chosen for further evaluation 
(Fig. 2.8a and 2.8b). These surface-exposed residues are located near the depression at the 2-fold axis of 
symmetry (Fig. 2.8c and 2.8f) and at the base of the three-fold protrusions (Fig. 2.8d and 2.8f). The 
stereographic roadmap projection of surface-exposed residues at the 3-fold axis of symmetry highlights 
the topological orientation of these 8 residues in relation to the surrounding amino acids at the capsid 
surface (Fig. 2.8g). As mentioned earlier, we also took into account that these amino acids were absent in 
the AAV1R8/19/20 variants that were unable to transduce the brain parenchyma following systemic 
administration.  
We then engineered a chimeric capsid by grafting the 8 amino acid residues from AAVrh.10 onto 
the AAV1 serotype, naming this chimera ‘AAV1RX’. We administered 6-8 week-old female C57/Bl6 
mice with AAV1RX-CBh-scGFP vectors at a dose of 5 x 1011 vg per mouse via tail vein injection. GFP 
reporter expression in the brain was assessed by immunostaining at 21 days post injection. As seen in Fig. 
2.8h, AAV1RX transduces neurons within the motor cortex and cortical neurons across the entire cortex 
while demonstrating limited transduction of glia and reduced vascular transduction, as seen earlier with 
the chimeric capsids AAV1R6 and AAV1R7. Continuing this trend, numerous GFP+ pyramidal neurons 
are observed in the hippocampus along with an abundance of GFP+ granular cells in the dentate gyrus. 
Notably, GFP+ glial and endothelial cells in these regions are largely absent. In the thalamus, AAV1RX 
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demonstrates robust neuronal transduction at levels comparable to AAV1R6 and AAV1R7 with modest 
transduction of glial and endothelial cells, albeit at levels higher than for other brain regions. In the 
hypothalamus, GFP+ neurons are sparse and few GFP+ glia and vascular endothelial cells are observed. 
Lastly, the preferentially neuronal transduction profile displayed by AAV1RX is also seen within the 
striatum (specifically, the caudate putamen) and amygdala (Fig. 2.8h). Quantitative analyses of these 
brain regions and comparisons to those seen for AAV1, AAVrh.10 and the chimeric AAV1R6 and 
AAV1R7 vectors suggest that this minimal footprint of 8 amino acid residues from AAVrh.10 is critical 
for crossing the BBB (Fig. 2.9).  
AAV1R6, AAV1R7 and AAV1RX mediate low transduction levels and biodistribution in 
peripheral tissues. To carry out a comparative analysis of different chimeric capsids with parental 
serotypes, 6-8 week old female C57/Bl6 mice were injected via tail vein with either AAV1, AAVrh.10, 
AAV1R6, AAV1R7 or AAV1RX vectors packaging a single-stranded luciferase reporter transgene driven 
by a chicken beta actin promoter (ssCBA-Luc) at a dose of 1 x 1011 vg per animal. At 2 weeks post 
injection, mice were sacrificed and tissues were harvested. Luciferase activity assays on tissue lysates as 
well as qPCR analyses to determine vector biodistribution were carried out (Fig. 2.10). All three chimeric 
vectors mediate higher luciferase transgene expression and a corresponding increase in viral genome 
copies, for each, is observed within the brain compared to AAV1 (Fig. 2.10a and 2.10b). However, their 
transgene expression levels and viral genome copy numbers were ~2-to-3-fold lower in the brain 
compared to AAVrh.10, which were all found to be statistically significant, with the exception of 
AAV1RX biodistribution (Fig. 2.10a and 2.10b). Similar transduction levels and viral genome copy 
numbers were observed for AAV1R6, AAV1R7 and AAV1RX in the heart, comparable to those seen for 
AAV1, despite some variation in cardiac transduction levels observed for AAV1RX (Fig. 2.10c and 
2.10d). AAVrh.10 mediates ~2-4-fold higher cardiac luciferase expression and correspondingly ~2-fold 
higher viral genome copies in the heart compared to the other vectors (Fig. 2.10c and 2.10d). As 
demonstrated by other groups, AAVrh.10 displayed several fold higher luciferase transgene expression 
levels and consistently high viral genome copies in the liver257. In contrast, low to background levels of 
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luciferase expression and significantly reduced viral genome copies were detected in the liver for AAV1, 
1R6, 1R7 and 1RX (Fig. 2.10e and 2.10f). It is noteworthy to mention that luciferase expression and a 
corresponding trend in viral genome copy numbers were detected for AAVrh.10 in the kidney (Fig. 2.10g 
and 2.10h). Although the three chimeric vectors showed similar viral genome copy number levels, 
luciferase expression in the kidney was absent. Taken together, these data seem to suggest that the 
chimeric AAV1R6, 1R7 and 1RX vectors are de-targeted from the liver and may be cleared from the 
blood circulation by the kidney. 
2.5. Discussion 
AAV1 and AAVrh.10, the parental serotypes used to generate the chimeric capsid library in this 
study, are both non-human primate isolates that belong to two different clades - AAV1 belongs to clade A 
while AAVrh.10 falls within Clade E246. Despite the evolutionary distance between them, they share 
~85% sequence homology between their Cap genes. AAV1 is known to recognize N-linked sialic acid 
(SIA) and the key residues composing the SIA recognition footprint on the AAV1 capsid have been 
recently reported117,118. The current study identified 262N, 263G, 264T, 265S, 267G, 268S, 269T and 
273T as key residues on the chimeric AAV1RX capsid, derived from AAVrh.10, that are essential for 
crossing the BBB. While none of the SIA contact residues for AAV1 are located within the chimeric 1RX 
footprint, the backbone carbonyl oxygen atoms of residues S268, D271, and N272 have been implicated 
in possibly stabilizing capsid-glycan interactions and increasing SIA binding affinity117. Furthermore, 
residues at this position (D271 and N272) are located within the galactose-binding footprint on AAV9269. 
Thus, although further studies will be required to identify and understand the exact nature of capsid-
glycan interactions for AAVrh.10 and the chimeric AAV1RX capsid, the current study supports the 
notion that residues within VR-I are critical.   
Alignment of the VP3 sequences of natural AAV isolates reveals that the 8 amino acid residues 
that confer the CNS phenotype to AAV1RX are conserved in AAVrh.8 and AAVrh.39, other neurotropic 
capsids in Clade E (Fig. 2.11). Similarly, AAV8 and AAVrh.43, also located within Clade E, demonstrate 
the ability to cross the BBB, albeit far less efficiently257. Both possess 7 out of the 8 residues in this 
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footprint; therefore, it is tempting to speculate that introducing the complete footprint onto these capsids 
will enhance their ability to cross the BBB. Although it is beyond the scope of the current study, we 
postulate that this footprint can potentially be grafted onto other serotypes such as AAV2, AAV6 and 
AAV7, amongst others, to confer the transvascular and neurotropic phenotype. Nonetheless, it should be 
noted that this minimal footprint may be less compatible with more divergent serotypes such as AAV4, 
AAV5 and AAV12. 
Phenotypically, AAV1 and AAVrh.10 differ markedly in their ability to cross the BBB and 
transduce neurons and glia in the brain. Several groups have now established that AAVrh.10 is also 
superior to AAV1 in terms of vector spread and transduction in peripheral tissues, when injected 
intravenously or within the CNS after direct intracranial injection257,258,270,271. Specifically, following 
direct tissue injections, such as intraparenchymal administration in the brain, AAV1 transduction is 
generally limited to the injection site272. When delivered intravenously, AAV1 demonstrates preferential 
uptake and transduction in vascular endothelial cells257,273. In contrast, AAVrh.10 appears not only to be 
taken up by and transduce vascular endothelial cells, but also to traverse the vasculature and transduce 
underlying tissue such as the CNS or skeletal muscle254,257. The current study identifies a minimum set of 
residues on the AAVrh.10 capsid that partially confers these traits to AAV1 capsids. While this minimal 
footprint on the AAV1RX chimera appears essential for traversing the BBB and transducing neurons, 
transduction in peripheral tissues such as the liver is markedly reduced, while cardiac expression remains 
similar to that of AAV1. These differences suggest that other structural domains on the AAVrh.10 capsid 
may play a role in imparting a systemic transduction profile. With regard to the brain parenchyma, it is 
important to note that after CNS entry, the post-entry transduction profile of AAV1RX is preferentially 
neuronal with decreased glial transduction compared to AAVrh.10. This can likely be attributed to the 
fact that the majority of the capsid is derived from AAV1, which is known to mediate a preferentially 
neuronal transduction following intracerebroventricular injections. Although speculative, it is also 
possible that the unknown mechanism by which 1RX crosses the BBB mediates preferential neuronal 
uptake or that additional motifs/amino acid residues on the AAVrh.10 capsid may mediate post-entry 
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steps in glial transduction. Ongoing work includes an incremental dose response study to evaluate 
vascular transduction mediated by AAV1RX and its apparent liver-detargeting, relative to AAVrh.10, and 
its relative efficiency across multiple doses.  
The precise mechanism of virus-host interactions utilized by the AAV1RX footprint to gain entry 
into the brain is currently unknown and is the focus of ongoing studies. As outlined earlier, it is plausible 
that capsid-glycan interactions on the endothelial cell surface determine whether viral capsids undergo 
transcytosis across the BBB. Another possible scenario is that AAV capsids can bind soluble, heavily 
glycosylated host factors in serum, which could confer the ability to traverse the BBB through interaction 
with cognate receptors. Our lab has shown that reduced glycan binding avidity is generally associated 
with prolonged blood circulation and the ability to traverse the vasculature. For instance, AAV2i8 and 
AAV9.45 are examples of AAV capsid variants that are liver de-targeted and capable of traversing the 
vasculature to transduce skeletal muscle274,275. It is therefore likely that the chimeric AAV1RX capsid has 
an altered affinity for SIA and recognizes other glycans that could confer the novel phenotype observed in 
this study. At this writing, it is unclear whether AAVrh.10 or AAV1R6/7/X, the novel capsid variants 
described in this study, cross the BBB by transiently disrupting the vasculature or by exploiting 
transcytosis mechanisms. It is also noteworthy to mention our observation that the liver-detargeted 
AAV1R variants display increased uptake in the kidney suggests a possible systemic AAV capsid 
clearance mechanism that warrants further investigation. Substantial biochemical and biological analyses 
will also be required to dissect the mechanism(s) underlying transvascular AAV transport.   
From a clinical perspective, capsids that can traverse the BBB, preferentially transduce neurons 
within the brain and that are simultaneously de-targeted from the liver could demonstrate an improved 
safety profile for CNS-targeted gene transfer applications from a systemic route of administration. 
Decreased vector uptake in peripheral organs, particularly the liver, could reduce the potential threat of 
hepatotoxicity, as evidenced by the transient elevation in transaminases in patient serum following 
systemic injection of certain AAV serotypes157,276,277. Additionally, our study indicates that systemic AAV 
vector clearance could potentially occur through the kidney, which might warrant further investigation   
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when evaluating the pharmacokinetics of AAV vectors in different animal models. The AAV1R6/7/X 
vectors could be broadly applicable for global CNS gene transfer and in particular, for developing gene 
therapy strategies to treat neurological disorders such as Friedreich’s Ataxia or spinal muscular atrophy. 
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Figure 2.1. Phylogenetic and structural analyses of the AAV1/rh.10 domain swap capsid library. 
(A) Schematic of the panel of representative AAV1/rh.10 chimeric capsids isolated from the library 
demonstrating sequence diversity, at the amino acid level, of domain swaps obtained through shuffling. 
Individual parental or chimeric capsids are listed vertically, while the VP1 capsid sequence with different 
domain swaps is displayed horizontally, from the N-terminus on the left to the C-terminus on the right. 
AAV1-derived residues are shown in gray, AAVrh.10 residues in green-cyan and consensus residues 
between the two in black. (B) Neighbor-joining phylogeny of the VP1 capsid sequences of AAV1/rh.10 
chimeric capsids. Capsid amino acid sequences were aligned with ClustalW and the phylogeny was 
generated using a neighbor-joining algorithm and a Poisson correction was used to calculate amino acid 
distances, represented as units of the number of amino acid substitutions per site. The tree is drawn to 
scale, with branch lengths in the same units as those of the evolutionary distances used to infer the tree. 
Bootstrap values were calculated with 1000 replicates and the percentage of replicate trees in which the 
associated taxa clustered together are shown next to the branches. (C) Three-dimensional surface models 
of capsid subunit trimer/3-fold symmetry axis regions of parental and representative chimeric AAV 
capsid mutants selected for in vivo screening. Amino acid residues derived from AAV1 are shown in gray 
while residues derived from AAVrh.10 are shown in green-cyan. Structural models were visualized and 
generated using PyMol.  
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Figure 2.2. In vivo screen yields AAV1/rh.10 chimeras capable of crossing the blood-brain barrier 
following intravenous administration. Scans of immunostained brain sections showing GFP expression 
in the cerebral cortex mediated by parental or chimeric vectors packaging a CBh-scGFP transgene at three 
weeks post administration via tail vein injection at a dose of 5 x 1011 vg (or PBS in the case of mock 
treatment). The global coronal brain section (top) indicates the boxed region of the cortex seen in the 
insets shown for each parental or chimeric vector, representing their individual transduction profiles. 
Scale bar = 100μm.  
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Figure 2.3. In vivo screen of AAV1/rh.10 chimeras for their ability to cross the blood-brain barrier 
and transduce various brain regions following intravascular administration. Mice received a dose of 
5 x 1011 vg of either parental (AAV1 or AAVrh.10) or chimeric vector packaging a CBh-scGFP 
transgene via tail vein injection. Immunostained and imaged mouse brain sections show GFP expression, 
as black/dark brown staining, at 21 days post injection Scale bar = 100 μm. The global coronal brain 
section at the top of the figure indicates the various brain regions shown in the insets: (A) MCT, motor 
cortex; (B) HC, hippocampus; (C) DG, dentate gyrus; (D) TH, thalamus; (E) HY, hypothalamus; (F) 
STR, striatum; (G) Amg, amygdala (n = 3 for each).   
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Figure 2.4. CNS transduction profile of AAV1R6 and AAV1R7 compared to parental AAV1 and 
AAVrh.10 in the brain. Transduction profiles at three weeks post tail vein injection of AAV vectors 
packaging a CBh-scGFP transgene at a dose of 5 x 1011 vg for parental serotypes, AAV1 and AAVrh.10 
(left columns), and for AAV1R6 and AAV1R7 (right columns) across various brain regions are shown, 
including the (A) motor cortex, (B) cerebral (somatosensory) cortex, (C) hippocampus, (D) dentate gyrus, 
(E) thalamus, (F) hypothalamus, (G) striatum, and (H) amygdala. Scale bar = 100μm.   
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Figure 2.5. Quantitative comparison of neuronal and glial transduction levels for parental and 
chimeric capsid variants. Relative neuronal transduction levels at 3 weeks post administration of vectors 
packaging a CBh-scGFP transgene via tail vein injection at a dose of 5 x 1011 vg were quantified by 
counting the number of transduced neurons and glia, identified based on morphology, for each brain 
region, per 50 μm coronal section. Transduction of parental serotypes, AAV1 and AAVrh.10, are shown 
alongside the chimeric variants, AAV1R6 and AAV1R7, across various regions of the brain, including 
the (A) motor cortex, (B) cerebral (somatosensory) cortex, (C) hippocampus, (D) dentate gyrus, (E) 
thalamus, (F) hypothalamus, (G) striatum, and (H) amygdala. Error bars represent standard deviation (n > 
or = 3). An unpaired two-tailed T-test with Welch’s correction and one-way ANOVA were used to 
demonstrate statistical significance for neuronal and glial transduction by each group relative to AAV1, 
and that differences between the means were statistically significant, respectively. ns, not significant; *, P 
< 0.05.  
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Figure 2.6. Relative cardiac and liver transduction by AAV1R6 and AAV1R7 compared to parental 
capsids. Either parental (AAV1 or AAVrh.10) or chimeric (AAV1R6 or AAV1R7) vectors packaging a 
CBh-scGFP transgene were administered at a dose of 5 x 1011 vg via tail vein injection. At 21 days post 
injection, heart and liver sections were immunostained for GFP and imaged. (A) GFP fluorescence for 
cardiac (top panel) and liver (bottom panel) tissues in mice treated with either PBS (Mock), AAV1, 
AAVrh.10, AAV1R6 or AAV1R7. (B) Transduction levels for cardiac (top) and liver (bottom) measured 
by quantifying relative fluorescence across multiple images taken for each treatment. The bars represent 
the range from lowest to highest values with the center line representing the average across samples. 
Relative fluorescence was normalized to mock treated tissues. Error bars represent standard deviation (n = 
3).  One-way ANOVA and unpaired two-tailed T-test with Welch’s correction for each group were 
carried out and significance relative to AAVrh.10 is shown. ns, not significant. *, P < 0.05.   
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Figure 2.7. Structural analysis of the AAV1R6 chimeric capsid variant. (A) The sequence 
alignment of AAV1R6 with AAV1 & AAVrh.10 highlights the amino acid residues (AAV1R6 
numbering) that are uniquely derived from AAVrh.10 (shown in black lettering and highlighted in blue). 
Conserved residues are lettered red and highlighted in yellow, while the non-conserved equivalent 
residues on AAV1 are shown in black or green text and are highlighted in either green or white. The 
Three-dimensional structural model of the chimeric AAV1R6 VP3 subunit (B) monomer was generated 
using SWISS-MODEL with the crystal structure of AAV8 serving as the template for homology 
modeling (PDB ID: 2QAO). Surface models of the AAV1R6 VP3 subunit (C) trimer dimer/2-fold axis of 
symmetry, (D) trimer/three-fold axis of symmetry, (E) pentamer/5-fold axis of symmetry and (F) Surface 
rendering of an intact AAV1R6 capsid (60mer) were generated via the VIPERdb oligomer generator and 
were visualized using PyMol. Residues derived from AAV1 are colored in gray while residues derived 
from AAVrh.10, clustered at the base of the protrusions at the 3-fold axis of symmetry, depression at the 
2-fold axis of symmetry and at the 5-fold pore, are colored in green cyan. 
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Figure 2.8. Rational design and functional mapping of a minimal AAVrh.10 footprint for crossing 
the BBB. (A) The sequence alignment of AAV1RX with AAV1 and AAVrh.10 shows the numbered 
amino acid residues within and adjacent to the neurotropic footprint. Conserved residues are highlighted 
in yellow, the residues composing the footprint are highlighted in cyan and non-conserved residues are 
highlighted in either green or white. Structural models of the engineered AAV1RX chimeric capsid were 
generated using SWISS-MODEL software for homology-based modelling and VIPERdb was used to 
generate oligomers. PyMol was used to generate surface rendered models of the AAV1RX VP3 subunit 
(B) monomer, (C) trimer dimer / 2-fold axis of symmetry, (D) trimer / three-fold axis of symmetry, (E) 
pentamer / 5-fold axis of symmetry and (F) the full capsid (60-mer). AAV1-derived amino acids and 
those homologous between AAV1 and AAVrh.10 are represented in gray while the residues comprising 
the neurotropic footprint from AAVrh.10 for crossing the BBB are depicted in green cyan. (G) The 
stereographic roadmap projection shows the neurotropic footprint as viewed down the threefold symmetry 
axis on the AAV1RX capsid and was generated using RIVEM. Only surface-exposed amino acid residues 
are shown, with the boundaries between each delineated with black lines. The green regions depict the 
topological protrusions at the three-fold axis of symmetry while the blue regions represent topological 
depressions. The key amino acid residues of this footprint are colored magenta (AAVrh.10 VP1 
numbering). (H) CNS transduction profile of AAV1RX packaging a CBh-scGFP transgene administered 
via tail vein injection at a dose of 5 x 1011 vg. Sections taken at 21 days post injection were 
immunostained and imaged. Scale bar = 100μm. 
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Figure 2.9. Quantification of neuronal and glial transduction levels mediated by AAV1RX 
compared to parental and other chimeric capsid variants. Mice received a dose of 5 x 1011 vg of 
either parental (AAV1 or AAVrh.10) or chimeric vector packaging a CBh-scGFP transgene via tail vein 
injection. At 3 weeks post injection, brains were taken, sectioned, immunostained for GFP and imaged. 
Relative neuronal and glial transduction levels were quantified by counting the number of transduced 
neurons and glia, identified based on morphology, for each region per 50 μm coronal section. AAV1RX 
transduction levels are shown alongside those for parental serotypes, AAV1 & AAVrh.10, as well as the 
chimeric variants, AAV1R6 and AAV1R7, (same data as in Fig. 4 of the main text), across various 
regions, including the (A) motor cortex, (B) cerebral cortex, (C) hippocampus, (D) dentate gyrus, (E) 
thalamus, (F) hypothalamus, (G) striatum, and (H) amygdala. Error bars represent standard deviation (n = 
3). An unpaired two-tailed T-test with Welch’s correction was used to demonstrate statistical significance 
of each group relative to AAV1. ns, not statistically significant; *, P < 0.05. One-way ANOVA was also 
used to demonstrate that differences among means are statistically significant. *, P < 0.05 for neuronal 
and glial transduction across all brain regions shown here.  
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Figure 2.10. Peripheral tissue transduction and biodistribution of AAV1R6, AAV1R7 and 
AAV1RX following intravenous administration. Mice were injected via the tail vein with PBS or with 
either AAV1, AAVrh.10, AAV1R6, AAV1R7 or AAV1RXvectors packaging a CBA-Luc reporter 
transgene at a dose of 1 x 1011 vg. At 2 weeks post-injection, (A) luciferase reporter transgene expression 
levels and (B) biodistribution of viral genome copies across various tissues were quantified. Luciferase 
expression levels were normalized to grams of tissue lysate and are represented as relative light units. 
Vector genome (vg) copies are normalized to mouse lamin B (mLamB) as an endogenous housekeeping 
gene and are represented as vg copies per cell. Error bars represent standard deviation (n = 3 for luciferase 
assays; n = 4 for biodistribution). One-way ANOVA and an unpaired two-tailed T-test with Welch’s 
correction for each group were carried out and significance relative to AAVrh.10 is shown. ns, not 
significant. *, P < 0.05.    
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Figure 2.11. Sequence alignment of 1RX footprint, and Variable Region I (VR-I) across common 
AAV serotypes. The sequence alignment of AAV1RX with common AAV serotypes highlights the 
amino acid residues (VP1 numbering) of the 1RX footprint, within the larger context of variable region I 
(VR-I), compared across common natural AAV serotypes. Black lines above and below demarcate the 
specific residues within the 1RX footprint. Key: Residues that are identical across serotypes are 
represented by red letters on a yellow background; conservative residues, blue letters on a cyan 
background; similar residues, black letters on a green background; weakly similar residues, green letters 
on a white background; non-similar residues, black letters on a white background. This sequence 
alignment was generated using Vector NTI Advance 11.5.2 software. 
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CHAPTER 3: CAPSID-SIALIC ACID INTERACTIONS INFLUENCE ADENO-ASSOCIATED 
VIRAL TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER2 
3.1. Overview 
Central nervous system (CNS) transduction by systemically administered recombinant adeno-
associated viral (AAV) vectors requires crossing the blood brain barrier (BBB). We recently mapped a 
structural footprint on the AAVrh.10 capsid, which when grafted onto the AAV1 capsid (AAV1RX) 
enables viral transport across the BBB; however, the mechanisms involved remain unknown. Here, we 
establish through structural modeling that this footprint overlaps in part with the sialic acid (SIA) receptor 
footprint on AAV1. In the current study, we test the hypothesis that altered SIA-capsid interactions may 
partly explain the ability of AAV1RX to traverse the BBB and subsequently transduce the CNS. We 
focused on a panel of AAV1 capsid variants with altered SIA footprints, which can be divided into three 
functional subgroups based on their relative SIA dependence. Specifically, capsids with ablated SIA 
binding show an improved ability to cross the BBB, although transduce the CNS with low-to-moderate 
efficiency. At the other end of the spectrum, the AAV1 capsid has a strong SIA dependency and does not 
cross the BBB after systemic administration; instead, AAV1 shows high levels of vascular transduction 
and is sequestered within the liver. The AAV1RX variant, which shows an intermediate SIA binding 
phenotype, is not only effective at crossing the BBB, but also transduces the CNS at levels comparable to 
AAVrh.10. In corollary, the reciprocal swap of the AAV1RX footprint onto AAVrh.10 (AAVRX1) 
attenuated CNS transduction relative to AAVrh.10. We conclude that the composition of residues within 
the capsid variable region I (VR-I) of AAV1 and AAVrh.10 appears to profoundly influence transport 
across the BBB, with altered SIA interactions playing a partial role in this phenotype. Further, we 
                                                          
 
2Contributing authors: Blake H. Albright, Kate Simon, Minakshi Pillai, Garth Devlin, and Aravind 
Asokan. K.S. and M.P. assisted in conducting animal experiments. G.D. performed tail vein injections. 
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postulate a “Goldilocks” model, wherein optimal glycan receptor interactions can influence BBB 
transport and CNS transduction of AAV capsids. 
3.2. Introduction 
Adeno-associated viral (AAV) vectors for gene therapy applications are being clinically 
evaluated for a range of genetic disorders affecting different tissue types11,130,140,142. One prime target for 
delivering therapeutic transgenes using AAV is the central nervous system (CNS). In particular, CNS-
targeted AAV vectors are being evaluated for treating a broad range of monogenic and neurodegenerative 
diseases afflicting the CNS, e.g., Spinal Muscular Atrophy (SMA), Parkinson’s, Alzheimer’s, Friedrich’s 
Ataxia and several lysosomal storage diseases, to name a few142,156,157,189,278. Understanding AAV-host 
interactions, particularly within the context of the CNS at the mechanistic level can help guide optimal 
design of recombinant AAV vectors for such therapeutic applications.  
AAV is a small, non-pathogenic, helper-dependent virus of the family Parvoviridae with a 4.7 kb 
ssDNA genome8. There have been a wide array of both natural and synthetic serotypes that have been 
discovered, which display broad tropisms across the host species, tissue and cellular levels11. These 
differential tropisms are ultimately determined by capsid structural features and capsid-host interactions 
afforded by that structure21.  The AAV capsid is a small (~25 nm) T=1 icosahedron composed of 60 viral 
protein (VP) monomers (VP1, VP2 and VP3 variants, assembled in a ratio of 1:1:10, respectively). The 
VP monomer is characterized by a conserved jellyroll, β-barrel structure that is comprised of 7 anti-
parallel β-strands. The interdigitating loop regions connecting these strands are highly variable regions 
(VRs) in sequence and highly plastic, being amenable to modification/mutation21. Furthermore, these 
surface-exposed loops determine the topology of the capsid surface, and have a profound effect on virus-
host interactions, dictating receptor usage, antigenicity, tissue tropism, and species specificity279.  
Principal amongst these virus-host interactions is the recognition of specific glycans, which serve 
as primary receptors for attachment8,20,36,55,248. Binding of the AAV capsid to primary glycan receptors at 
the cell surface serves as the initial step in the lifecycle of AAV. This is then followed by subsequent 
interactions with host factors such as AAVR leading to endocytic uptake, intracellular trafficking steps 
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and nuclear entry leading to transduction22,126,280. The glycan receptors for numerous AAV serotypes have 
been identified. Examples include recognition of heparan sulfate (AAV2/3), sialic acid (SIA, 
AAV1/4/5/6), galactose (GAL, AAV9), and N-acetyl lactosamine (LacNAc, 
AAVrh.10)68,85,113,116,119,281,282. Specifically, AAV1 & AAV6 recognize both α2,3 and α2,6 N-linked SIA. 
AAV5 also recognizes N-linked SIA, while AAV4 uniquely recognizes α2,3 O-linked SIA (mucin)85. 
From a structural perspective, the structures of various AAV capsids complexed with their cognate glycan 
receptors have further pinpointed glycan binding sites to the protrusions at the 3-fold axis of symmetry on 
the capsid38. The residues and locations on the AAV capsid surface that influence such interactions, 
referred to as receptor footprints, are now known for AAV1, 2, 3, 4, 5, 6, and 968,113,116,283. 
Different AAV serotypes exhibit various CNS tropisms, and our understanding of the role of 
glycans in dictating these cellular tropisms is expanding. CNS tropism and transduction profiles can vary 
drastically based on the route of AAV administration in different hosts (e.g., intravascular, 
intracerebrospinal fluid (CSF), or intraparenchymal)157. Notably, certain serotypes, AAV9, AAVrh.8, and 
AAVrh.10, are able to traverse the BBB following systemic administration and enter the brain 
parenchyma to efficiently transduce cells within the CNS98,230. However, the capsid-glycan interactions 
that might influence the mechanisms underlying AAV capsid transport across the BBB into the CNS are 
not well understood. Towards furthering this understanding, our lab recently identified structural 
determinants on the AAVrh.10 capsid, which when grafted onto the AAV1 capsid permits BBB 
transport284. The engineered AAV1RX variant demonstrates marked transduction of neurons across 
multiple brain regions and reduced tropism for glial and vascular endothelial cells in the brain. To further 
understand the mechanisms underlying such transendothelial transport into the CNS, we extensively 
characterized several AAV capsid variants displaying a range of SIA interactions in the current study. We 
postulate a model, wherein the glycan binding affinity of AAV capsids inversely correlates with their 
ability to traverse the blood-brain barrier.   
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3.3. Methods 
Generation of mutant AAV plasmid constructs. Mutant AAV plasmid constructs were cloned 
using site-directed mutagenesis via the QuikChange Lightning site-directed mutagenesis kit (Agilent 
Technologies, catalog no. 200518) according to the manufacturer’s protocol. The following primer pairs 
were used to generate the single-amino acid changes onto the pXR1 (AAV1) backbone for AAV1-N447S 
(forward, 5′-CCAATACCTGTATTACCTGAGCAGAACTCAAAATCAG -3′; and reverse, 5′- 
CTGATTTTGAGTTCTGCTCAGGTAATACAGGTATTGG -3′) and for AAV1-W503A (forward, 5 ′- 
CAACAGCAATTTTACCGCTACTGGTGCTTCAAAATATAACC-3′; and reverse, 5′- 
GGTTATATTTTGAAGCACCAGTAGCGGTAAAATTGCTGTTG-3′). The following primer pair was 
used to generate the AAVRX1 mutant onto the pXRrh.10 (AAVrh.10) backbone: (forward, 5′- 
CAGCAACGACAACCACTACTTCGGCTACAGCACCCCCTGG -3′; and reverse, 5′- 
GCCCCCGTTGAAGCACTGGAGATTTGCTTGTAGAGGTGGTTGTTGTAGG -3′; IDT 
Technologies, Ames IA). 
Cell culture. HEK293 cells were cultured in Dulbecco’s modified eagle medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher, Waltham, MA) and 1% penicillin, 
streptomycin (P/S, Thermo Fisher), in 5% CO2 at 37⁰C. MB114 (mouse brain microvascular endothelial), 
U87 (human astrocytoma), and Neuro2a (mouse neuroblastoma) cell lines were all cultured as described 
above, except they were cultured with DMEM supplemented with 5% FBS and 1% P/S. Gratefully, we 
received the MB114 cell line as a gift from Linda Van Dyk, University of Colorado.  
Virus production and titers. Recombinant AAV vectors were produced using an updated triple 
plasmid transfection method described previously15,285. A capsid-specific helper plasmid (i.e. pXR1, 
pXRrh.10, pXR1RX, pXRRX1, pXR1-N447S, or pXR1-W503A) an adenoviral helper plasmid 
(pXX680), and with a transgene packaging cassette, encoding either self-complimentary green fluorescent 
protein driven by a chicken beta actin hybrid promoter (pTR-CBh-scGFP) or luciferase driven by the 
chicken beta actin promoter (pTR-CBA-Luc), flanked by AAV2 inverted terminal repeat (ITR) 
sequences. Viral vectors were harvested and were purified via iodixinol density gradient 
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ultracentrifugation. Viral vectors were further subjected to buffer exchange and concentration using 
Sartorius Vivaspin6 100 kDa molecular weight cut-off (MWCO) centrifugation columns (F-2731-100 
Bioexpress, Kaysville, UT). Purified virus preparations were titered by quantitative PCR with primers 
amplifying the AAV2 ITR regions. (forward, 5’- AACATGCTACGCAGAGAGGGAGTGG –3’; reverse, 
5’-  ATGAGACAAGGAACCCCTAGTGATGGAG -3’; IDT Technologies, Ames IA).  
In vitro transduction assays. Various cell lines were seeded in 24-well plates at a density of 1 x 
105 cells per well and allowed to adhere overnight at 37⁰C. The following day, cells were incubated with 
virus at a multiplicity of infection (MOI) of 10,000 vector genomes (vg) per cell and were incubated in 
5% CO2 at 37⁰C. At 48 h post infection, cells were lysed using 150 μl of 1x passive lysis buffer 
(Promega) for 20 minutes at room temperature. 50 μl of each cell lysate was then transferred to an assay 
plate and luciferase reporter transgene expression levels were quantified using a Victor 3 multilabel plate 
reader (Perkin-Elmer) immediately after adding 50 μl of luciferin (Promega) to each well. 
Enzymatic desialylation assays. MB114 mouse brain microvascular endothelial cells were seeded 
in 24-well plates at a density of 1 x 105 cells per well and allowed to adhere overnight at 37⁰C. The 
following day, cells were pretreated with 50 mU/ml neuraminidase type III (from Vibrio cholera, Sigma 
N7885) or with 1x PBS as a negative control, in serum-free DMEM at 37⁰C for 2 h. Cells were then 
washed three times with 1x PBS, were given fresh DMEM containing 5% FBS and 1% P/S and were 
incubated with virus at an MOI of 10,000 vg per cell at 37⁰C. At 24 h post infection, cells were lysed and 
luciferase transgene expression levels were assayed as described earlier for the in vitro transduction 
assays.  
Cell surface binding assays following enzymatic desialylation. MB114 mouse brain 
microvascular endothelial cells were seeded in 24-well plates at a density of 1 x 105 cells per well and 
allowed to adhere overnight at 37⁰C. The following day, cells were pretreated with 50 mU/ml 
neuraminidase type III (from Vibrio cholera, Sigma N7885) in serum-free DMEM at 37⁰C for 2 h. Cells 
were then washed three times with 1x PBS, were given fresh DMEM containing 5% FBS and 1% P/S. 
Cells were then pre-chilled at 4⁰C for 30 min prior to incubation with virus at an MOI of 10,000 vg/cell 
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for 1 h at 4 ⁰C. Cells were then washed three times with ice-cold 1x PBS to remove unbound virions 
before adding 200 μl of molecular biology grade water to each well. Cells were subjected to three freeze-
thaw prior to collection of cell lysates along with cell surface-bound virions. Viral genome copy numbers 
of cell-surface bound virions were then quantified using quantitative PCR (qPCR) with primers specific 
to the luciferase transgene (forward, 5′- AAAAGCACTCTGATTGACAAATAC -3′; and reverse, 5′- 
CCTTCGCTTCAAAAAATGGAAC -3′). Viral genome copy numbers were then normalized to the 
mouse lamin B2 housekeeping gene using the following primer pair: forward, 5′- 
GGACCCAAGGACTACCTCAAGGG -3′; and reverse, 5′- AGGGCACCTCCATCTCGGAAAC -3′. 
The number of viral genomes are represented as the ratio of vg/cell and were plotted as fold-change 
relative to the respective untreated control samples. 
Animal studies.  All animal experiments were performed using 6-to-8-week-old female C57/BL6 
mice purchased from Jackson Laboratories (BAR Harbor, ME). These mice were maintained and treated 
in compliance with NIH guidelines and as approved by the UNC Institutional Animal Care and Use 
Committee (IACUC). Recombinant AAV vectors packaging a CBh-scGFP transgene or 1x PBS (as mock 
treatment) were administered at a dose of 5 x 1011 vg via tail vein injection. Animals were sacrificed three 
weeks post injection with an intraperitoneal injection of tribromoethanol (Avertin) (0.2 ml of 1.25% 
solution) followed by transcardial perfusion with 30 ml of 1x PBS followed by 30 ml of 4% 
paraformaldehyde in PBS. Tissues were extracted, were post fixed for 48 h, and brain and  liver tissues 
were sectioned (generating 50-μm-thick sections) using a Leica VT 1200S vibrating blade microtome 
(Leica Biosystems, IL). Brain sections were then immunostained as described below.  
Tissue processing and histological analysis. Free-floating 50-μm-thick coronal brain sections 
were stained in 24-well plates. First, sections were blocked with buffer containing 10% goat serum and 
1% Triton X (Sigma-Aldrich) in 1x PBS for 1 hour at room temperature. The primary antibody incubation 
was then performed at 4⁰C overnight with a primary monoclonal rabbit α-GFP antibody (Life-
Technologies-G10, 362 1:750) diluted in blocking buffer. The next day, three 10 minute washes were 
performed with 1x PBS and subsequent immunostaining was performed using the Vectastain ABC kit 
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(Rabbit IgG PK-4001 kit, Vector biolabs, Burlingame, CA). Immunostained brain sections were finally 
mounted onto microscopy slides and were digitally imaged in bright field (20x objective) using an Aperio 
ScanScope XT instrument (Aperio Technologies, Vista, CA) by the UNC Translational Pathology 
Laboratory. Images were obtained using Leica eSlide Manager (centralized image storage and data 
management software) and analyzed using Aperio ImageScope and WebViewer software. Quantifications 
of cellular transduction were calculated by counting the number of GFP+ neuronal or glial cells, 
determined based upon morphology, per 50 μm coronal brain section. Data was graphed and statistical 
analyses were performed as outlined above. Specific brain regions were identified based upon comparison 
to a coronal mouse brain reference obtained from the Allen Mouse Brain Atlas. To assay for GFP 
expression in the liver, sections were stained with the anti-GFP primary antibody as described above; 
however, an anti-rabbit goat antibody conjugated to Alexa-488 was instead used as the secondary 
antibody at a dilution of 1:500 (anti-rabbit Abcam-96,883). These sections were then imaged with an 
EVOS FL epifluorescence cell imaging system (AMC/Life Technologies) using the GFP light cube 
(excitation 470 nm, emission 510 nm). Relative fluorescence was quantified from these images using 
ImageJ software and data was plotted and statistical analyses were carried out as described earlier, using 
GraphPad Prism7® software. 
Vector genome biodistribution. Animal studies were performed as described above. DNA was 
extracted and purified from paraformaldehyde-fixed 50-μm-thick tissue sections using the QIAamp DNA 
FFPE Tissue Kit (QIAGEN, Cat No. 56404). Viral genome copy numbers were then determined for each 
tissue using quantitative PCR with primers specific to the chicken beta actin (CBA) promoter/CMV 
enhancer element sequence driving the CBh-GFP transgene (forward, 5′- 
TGTTCCCATAGTAACGCCAA -3′; and reverse, 5′- TGCCAAGTAGGAAAGTCCCAT -3′). These 
viral genome copy numbers were then normalized to the mouse lamin B2 housekeeping gene using the 
primers (forward, 5′- GGACCCAAGGACTACCTCAAGGG -3′; and reverse, 5′- 
AGGGCACCTCCATCTCGGAAAC -3′). The biodistribution of viral genomes are represented as the 
ratio of vector genomes per cell recovered for each tissue.  
 63 
Structural modeling. Previously published amino acid sequences and coordinates for the AAV1 
VP3 structure (PDB ID, 3NG9) were used to generate three-dimensional homology models for the capsid 
variants seen here263. SWISS-MODEL (http://swissmodel.expasy.org/) was used for structural prediction 
based on homology to the AAV1 capsid264. Subsequently, a structure-based alignment was generated 
using the secondary structure matching (SSM) application in the WinCoot software, again using AAV1 
VP3 monomer as a template205,265,286. The VIPERdb oligomer generator utility 
(http://viperdb.scripps.edu/oligomer_multi.php) was then used to generate oligomeric structural models of 
the VP3 trimer/3-fold symmetry axes, the VP3 trimer dimers/2-fold symmetry axes, and the full capsid 
(60mers)266. Lastly, PyMOL (Molecular Graphics System, Schrödinger LLC, http://www.pymol.org/) was 
used visualize surface-rendered depictions of these models. 
Data and Statistical Analysis. All quantitative data was plotted and statistical analyses were 
carried out using the GraphPad Prism 7® software.  One-way Anova was used to demonstrate statistical 
significance. ns, not significant; *, p < 0.05.  
3.4. Results 
Characterization of AAV capsid variants spanning the SIA sensitivity spectrum. We hypothesized 
that altered SIA interactions might be involved in the mechanism by which AAV1RX is able to cross the 
BBB and transduce cells within the brain parenchyma. To investigate such a relationship, we first selected 
several AAV capsid variants possessing differential affinities for binding α2,3- and 2,6- N-linked Sialic 
acid (SIA), the primary glycan receptor for AAV1. First, we included AAV1RX, as well as its parental 
serotypes – AAV1, which binds SIA with high affinity, as a positive control, and AAVrh.10, which does 
not bind SIA, as a negative control (Fig. 3.1a). We also generated the AAVRX1 capsid variant to further 
interrogate the 1RX footprint, by performing the reciprocal swap relative to AAV1RX (Fig. 3.1b). 
Briefly, AAV1RX was generated by grafting a stretch of 8 residues from the variable 1 region (VR1) of 
AAVrh.10 onto the AAV1 capsid. In contrast, AAVRX1 was generated by grafting the corresponding 
residues from AAV1 onto the AAVrh.10 backbone. Additionally, we generated two AAV1-based capsid 
mutants harboring single amino acid substitutions – AAV1-N447S and AAV1-W503A, in which the 
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asparagine at position 447 (AAV1 VP1 numbering) has been substituted for serine or in which the 
tryptophan at position 503 has been substituted for an alanine, respectively (Fig. 3.1c & 3.1d). These 
mutations have been previously published and both the asparagine at position 447 and the tryptophan at 
position 503 have been shown to be located within the AAV1 SIA binding pocket and play a direct role in 
binding SIA as direct contact residues283. Accordingly, these mutations have both been shown to result in 
diminished SIA binding for AAV1. Structural models of these capsid variants, showing both the full 
capsid (60mer) as well as the three-fold axis of symmetry/trimer are shown (Fig. 3.1).  
We first evaluated the infectivity of these capsid variants by performing in vitro transduction 
assays on three biologically relevant CNS-derived cell lines – the Neuro2a mouse neuroblastoma cell line, 
the U87 human astrocytoma cell line, and the MB114 mouse brain microvascular endothelial cell line 
(Fig. 3.2). These cells were infected with each capsid variant at a multiplicity of infection of 10,000 
vg/cell and infection was carried out for 48 h.  In the case of the Neuro2a cell line, transduction by most 
capsid variants seemed to phenocopy either AAV1, producing relatively high transduction levels, or they 
phenocopied AAVrh.10, demonstrating transduction levels that were roughly a log-fold lower (Fig. 3.2a). 
Despite some variation in transduction levels, the overall transduction profiles observed for the U87 cell 
line were similar, again yielding two groups, behaving either more AAV1-like or more AAVrh.10-like 
(Fig. 3.2b). Only in the case of the MB114 mouse brain microvascular cell line did we see these capsid 
variants demonstrate a more intermediate phenotype, showing substantial (~ 0.5 - 1.5 log-fold) 
differences, relative to either AAV1 or AAVrh.10. Based upon this observation, as well as upon the 
physiological relevance in terms of the BBB, we selected the MB114 brain microvascular cell line for 
further experiments to assess the dependency of these capsids on sialic acid for cell surface attachment 
and transduction. 
Capsid variants display differential sensitivities to removal of cell-surface SIA. We next wanted 
to evaluate the dependency of these capsids on the presence of cell surface SIA. To do so, we performed 
in vitro transduction assays on MB114 cells following pretreatment with either serum-free media (as a 
negative control) or with 50 mU/ml of neuraminidase (type-III, from Vibrio cholera), which 
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enzymatically removes terminal sialic acid residues from the cell surface (Fig. 3.3a). As expected, AAV1 
is highly sensitive to removal of cell-surface SIA, resulting in a roughly 1.5-log decrease in transduction 
following treatment. In contrast, AAVrh.10, which binds LacNAc, does not appear to depend upon cell 
surface SIA for transduction, as treatment with neuraminidase had no effect on transduction. Similarly, 
both AAVRX1 as well as AAV1-N447S transduction appeared to be SIA-independent, as they were 
unaffected by neuraminidase treatment. However, a third functional group can be observed for other 
capsid variants. Both AAV1RX, and, to a slightly lesser extent, AAV1-W503A demonstrated an 
intermediate sensitivity to enzymatic removal of cell surface SIA with moderate, yet significant decrease 
in transduction levels (roughly 2-fold, or 1.5-fold, respectively). 
Having observed differential sensitivities of these capsid mutants to enzymatic removal of cell 
surface SIA in terms of transduction levels, we next wanted to determine whether this finding would 
correlate to cell surface binding of virions. Thus, we performed binding assays measuring viral genomes 
(vg) bound per cell and plotted the data as fold-change following desialylation using neuraminidase 
treatment (Fig. 3.3b). Consistent with the transduction profile, AAV1 binding was found to be highly 
dependent on the presence of SIA, as desialylation results in a nearly 2-log decrease in bound viral 
genomes per cell. Further, AAVrh.10 binding appears to be independent of SIA, as desialylation did not 
result in any decrease in the number of bound virions detected per cell. Likewise, cell surface attachment 
for both AAV1-N447S and AAVRX1 does not depend on the presence of SIA. Lastly, the intermediate 
functional group identified in the transduction assays is recapitulated here as well – AAV1RX, and again, 
to a lesser degree, the AAV1-W503A mutant both show moderate sensitivities to removal of cell surface 
SIA, demonstrating roughly a 1.25 log-fold and near log-fold decrease in the number of bound vg 
following neuraminidase treatment. To summarize, AAV1, the sole capsid in functional group I, binds 
SIA with relatively high affinity while the capsids in group III, AAVrh.10, AAVRX1, and AAV1-N447S 
do not possess any capacity to bind SIA. Furthermore, this data suggests that the capsids in functional 
group II, AAV1RX and AAV1-W503A both retain the ability from their parental AAV1 to recognize 
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SIA, however their affinity for SIA is reduced, with AAV1-W503A showing an even greater reduction in 
SIA binding affinity than seen for AAV1RX.  
SIA binding affinity inversely correlates with BBB transport and CNS transduction. Having 
observed these different functional groups in terms of sensitivities to enzymatic removal of cell-surface 
terminal SIA residues from in vitro transduction and binding assays, we next wanted to see if these results 
would correlate with in vivo transduction assays. In particular, we hypothesized that differential SIA 
binding affinities displayed by these capsid mutants would correlate with differential capacities for BBB 
transport and CNS tropism/transduction following systemic administration. Thus, we administered 
AAV1, AAVrh.10, AAV1RX, or one of the two mutant capsids, AAV1-N447S and AAV1-W503A, 
packaging a CBh-GFP reporter cassette at a dose of 5 x 1011 vg per mouse (~ 2.5 x 1013 vg/kg) via tail 
vein injections in C57/Bl6 mice. Additionally, we also administered the reciprocal swap variant, 
AAVRX1, at the same dose in order to evaluate the 1RX footprint outside the context of SIA interactions 
via ablation of the footprint on AAVrh.10. At 21 days post injection, mice were sacrificed, tissues were 
removed, processed, and 50 μm coronal brain sections were immunostained for GFP. These sections were 
then scanned in bright field at 20x magnification and representative images were taken from multiple 
brain regions in order to assess GFP transgene expression throughout the brain parenchyma. We have 
included representative images for multiple brain regions – including the cerebral cortex, showing both 
the somatosensory cortex (SCT, Fig. 3.4a) and the motor cortex (MCT, Fig. 3.4b). We also evaluated 
transduction profiles in the hippocampus, visualizing CA1/2 pyramidal neuron layers (Fig. 3.4c) and the 
dentate gyrus (Fig. 3.4d). We assessed transduction in the striatum (caudoputamen) region of coronal 
lateral ventricle sections (Fig. 3.4e). We also visualized transduction in the thalamus (Fig. 3.4f) and 
hypothalamus (Fig. 3.4g). Qualitative trends in these regions are further corroborated by quantitations of 
GFP+ neurons and glia, in the cortex (CTX, Fig. 3.5a), the hippocampus (HC, Fig. 3.5b), and the striatum 
(STR, Fig. 3.5c).  
AAV1, which is a capsid highly dependent on SIA interactions, fails to undergo transvascular 
transport across the BBB. Consistent with prior reports, we observed that, following intravascular 
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administration, AAV1 transduction is limited to microvascular endothelial cells across each region of the 
brain that we evaluated. Negligible numbers of GFP+ neurons and glial cells were observed, regardless of 
brain region, emphasizing the known vascular sequestration phenotype for AAV1.  
AAVrh.10 does not bind SIA and is a neurotropic capsid characterized by its ability to efficiently 
cross the BBB and mediate high levels of gene transfer in the CNS.  Due to its known neurotropic 
phenotype, AAVrh.10 was included as a positive control for BBB transport and CNS transduction. 
Accordingly, AAVrh.10 demonstrates robust transduction of neurons, glia and vascular endothelial cells 
across the cerebral cortex, including the SCT (Fig. 3.4a) and the MCT, as well as for overall quantitations 
of cortical expression (Fig. 3.5a). In the case of AAVrh.10, we also observe substantial variation in terms 
of the intensity of immunostained GFP+ cells, contributing to the variation we observe measurements in 
number of GFP+ cells across brain sections from different mice. Interestingly, we also frequently observe 
a pronounced gradient in terms of transduced neurons in the cortex (Fig. 3.4a and 3.4b). Specifically we 
observe a high density of GFP+ neurons in cortical layers 1-3, which lie at the periphery of the 
parenchyma. This density in GFP+ cortical neurons decreases across layers 4-6. This observation is 
consistent with previous studies performed by our lab. Similarly, AAVrh.10 transduces neurons, glia and 
endothelial cells in the hippocampus, including pyramidal neuron layers (Fig. 3.4c) and the DG (Fig. 
3.4d), as well as for overall levels of hippocampal neuron and glial expression (Fig. 3.5b).  AAVrh.10 
transduces all cell types with high efficiency, indicating efficient BBB transport within the STR (Fig. 3.4d 
and Fig. 3.5c), as well as within both the thalamus (Fig. 3.4e) and the hypothalamus (Fig. 3.4f).  
AAV1RX is more moderately dependent on SIA for binding, efficiently traverses the BBB, is 
neurotropic, and mediates high transduction levels in the brain parenchyma. Upon systemic 
administration, we observe high levels of neuronal transduction across the somatosensory (Fig. 3.4a) and 
motor cortices (Fig. 3.4b). Neuronal expression levels are only marginally lower than those observed for 
AAVrh.10 across the entire cortex, while AAV1RX demonstrates a 2-fold decrease in glial transduction 
alongside greatly diminished vascular transduction, relative AVrh.10 (Fig. 3.5a). Again, AAV1RX 
recapitulates previous data, showing robust neuronal transduction at levels only marginally lower than 
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those for AAVrh.10 in the hippocampus while transducing ~5-fold fewer glial cells than AAVrh.10 (Fig. 
3.5b). This trend is evident for both pyramidal neuronal layers (Fig. 3.4c) and granular layers in the 
dentate gyrus (Fig. 3.4d). We see a similar trend in other brain regions, where we observe a robust 
number of GFP+ neurons with relatively fewer GFP+ glia in the striatum (Fig. 3.4e) and thalamus (Fig. 
3.4f). In the hypothalamus; however, AAV1RX seems to transduce lower levels of both neurons and glia 
(Fig. 3.4g). Whereas in other brain regions we do see a modest decrease in AAV1RX neuronal 
transduction levels compared to AAVrh.10, AAV1RX transduces striatal neurons at levels equal to 
AAVrh.10 while simultaneously showing a greater than 2-fold decrease in glial transduction (Fig. 3.5c).  
AAV1-N447S and AAV1-W503A are capsid mutants with defective SIA binding and demonstrate 
inefficient BBB transport and low CNS transduction levels. We next wanted to evaluate our two AAV1-
based mutants. AAV1-W503A demonstrated a moderate (although further diminished relative to 
AAV1RX) dependency on SIA interactions for in vitro transduction and binding. The other capsid 
mutant, AAV1-N447S, which does not use SIA, was evaluated in tandem. Both mutants, when injected 
intravenously, demonstrate increased uptake across the BBB and equivalent increases in neuronal and 
glial transduction levels, relative to AAV1, as evidenced by roughly 20-fold and 2-fold increases in the 
numbers of GFP+  cortical neurons and glia detected, respectively (Fig. 3.5a). Interestingly, we also 
observed lower levels of vascular transduction for AAV1-W503A; however, AAV1-N447S mediated 
considerable GFP expression in the vasculature (Fig. 4a and 4b). AAV1-N447S additionally produced a 
gradient of transduction across the cortical neuron layers and in some paraventricular regions, similarly to 
AAVrh.10. However, this was not observed in all samples, particularly for those exhibiting lower overall 
expression. Despite an observable increase in the amount of GFP+ neurons and glia in the cortex relative 
to AAV1, mean AAV1-W503A and AAV1-N447S, transduction levels averaged only ~ 5-8% and ~ 22-
25% of those observed for AAV1RX, in regards to neurons and glia, respectively. Throughout the 
hippocampus, the SIA-binding defective mutants show the same general trend, across pyramidal neuron 
layers (Fig. 3.4c) and the dentate gyrus (Fig. 3.4d). Both mutants mediate roughly equivalent neuronal 
transduction levels, ~3-8-fold higher than AAV1, and glial transduction levels equivalent to AAV1 (Fig. 
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3.5b). Nonetheless, there is a significant difference in the number of GFP+ hippocampal neurons 
observed for both mutants relative to AAV1RX, which demonstrated an approximately log-fold higher 
neuronal transduction level and a roughly half-log difference in the number of transduced glia. In the 
striatum, both mutants mediate roughly equivalent transduction profiles compared to other brain regions, 
although more sample-to-sample variation is seen for AAV1-W503A, consistent, with its greater, yet 
modest, SIA affinity (Fig. 3.4e). Here, we see a modest increase in transduction levels for both mutants 
relative to AAV1, with ~3-4-fold higher numbers of GFP+ striatal neurons and ~1.5-fold more GFP+ glia 
(Fig. 3.5c). Nonetheless, a significant log-fold decrease in the number of GFP+ striatal neurons, is 
observed for AAV1-N447S and AAV1-W503A, compared to AAV1RX (Fig. 3.5c). Consistent with the 
results described above, few GFP+ neurons and glia are seen for either mutant in the thalamus indicating 
only marginal improvement in BBB transport and/or transduction, relative to their wildtype AAV1 capsid 
(Fig. 3.4f). Lastly, few GFP+ neurons or glia are seen in the hypothalamus for either mutant, while low-
to-moderate levels of vascular transduction are seen in the hypothalamus for all capsid variants. In 
general, we observed a trend in which SIA binding affinity seems to inversely correlate with transvascular 
transport across the BBB and transduction of the brain parenchyma. 
AAVRX1, the reciprocal swap relative to AAV1RX, demonstrates attenuated BBB transport and 
CNS transduction relative to AAVrh.10. Lastly, we evaluated AAVRX1, the other remaining capsid 
variant that does not bind SIA. Across the cortex, we see that intravascularly administered AAVRX1 does 
transduce neurons and glia in the brain, as observed in the somatosensory (Fig. 3.4a) and motor (Fig. 
3.4b) regions of the cortex; however, these transduction levels are markedly reduced, with ~22% and 
~26% of the number of GFP+ cortical neurons and glia, respectively, compared to those observed for 
AAVrh.10 (Fig. 3.5a). AAVRX1 also transduced the brain microvasculature similarly to AAVrh.10, 
assessed visually (Fig. 3.4). Interestingly, we found that AAVRX1 seems to phenocopy AAVrh.10 in 
terms of the aforementioned gradient in the density of GFP+ cells across cortical neuron layers; 
furthermore, we see an even greater number of more faintly stained GFP+ cells relative to AAVrh.10. 
AAVRX1 exhibited a significant log-fold decrease in neuronal transduction and a 2-fold decrease in glial 
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transduction, relative to AAVrh.10 in both the hippocampus (Fig. 3.4c-d and Fig. 3.5b) and in the 
striatum (Fig. 3.4e and Fig. 3.5c). Lastly, while AAVRX1 continues to show noticeably fewer GFP+ 
neurons and glia relative to AAVRh.10 in the thalamus (Fig. 3.4f), it appears to behave similarly to 
AAVrh.10 in the hypothalamus, showing similar albeit slightly lower numbers of GFP+ hypothalamic 
neurons and similarly sparse GFP+ glia (Fig. 3.4g).  
Effect of SIA binding on liver tropism and transduction. In comparison with AAV1, which 
transduces the liver with moderate efficiency, AAVrh.10 is known to exhibit pronounced hepatotropism 
following intravenous administration and mediates very high liver transduction. Our lab recently showed 
that upon intravenous injection in mice, AAV1RX is detargeted from the liver despite maintaining robust 
CNS transduction. Having found that AAV1RX demonstrates reduced SIA interactions in vitro, which 
correlate with its CNS phenotype, we hypothesized that interference with capsid-SIA interactions could 
also explain the decreased liver tropism and transduction observed in the case of AAV1RX. Briefly, we 
evaluated GFP reporter expression in liver samples from mice that were intravenously injected with either 
AAV1, AAVrh.10, AAV1RX, AAVRX1, AAV1-N447S or AAV1-W503A, each packaging a CBh-GFP 
reporter cassette, at a dose of 5 x 1011 vg/mouse. Liver sections were immunostained for GFP reporter 
expression and were imaged using a fluorescent microscope to assess GFP transgene expression (Fig. 3.6a 
and 6c). GFP expression was then quantified using ImageJ software in order to measure average 
fluorescence for multiple images per mouse (Fig.3.6b and 3.6d). Consistent with previous studies, we 
observed moderate GFP expression levels for AAV1 and extremely low GFP expression for AAV1RX in 
the liver. Next, we evaluated AAV1-W503A, which displays further reduced, yet still moderate SIA 
binding affinity relative to AAV1RX. Consistently, AAV1-W503A also exhibits extremely low GFP 
expression in the liver and is similarly liver-detargeted, relative to AAV1 (Fig. 3.6a and 3.6b). 
Interestingly, the AAV1-N447S mutant, which unlike the W503A mutation, exhibits complete 
independence from SIA interactions for in vitro transduction and binding, is not liver-detargeted. AAV1-
N447S actually shows increased GFP expression in the liver relative to AAV1, although substantial 
variability in GFP expression levels was observed across different tissue samples (Fig. 3.6b).  
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We also evaluated the transduction profile for AAVRX1 in the liver alongside AAV1, AAV1RX 
and AAVrh.10. Consistent with previous studies, the hepatotropic AAVrh.10 capsid exhibited extremely 
high GFP expression in the liver. Interestingly, despite having exhibited attenuated CNS transduction, 
AAVRX1 was found to retain the liver tropism of its parental AAVrh.10 capsid. Equivalent, if not higher, 
GFP expression levels were observed for AAVRX1 in the liver, compared to AAVrh.10 (Fig. 3.6c and 
3.6d).  Because of oversaturation of the fluorescent signal due to the extremely high intensity of GFP 
expression observed for AAVrh.10 and AAVRX1, we captured images using a lower (1%) intensity 
setting on the microscope and these representative images are shown in a separate panel (Fig. 3.6c) 
compared to the images taken at a higher intensity setting (10%) shown in Fig. 3.6a. All quantifications of 
relative fluorescence, however, were measured using images captured at the 10% intensity setting.  
Structural analysis of the 1RX footprint within the context of the AAV1 SIA binding pocket. We 
recently mapped the coordinates of the AAV1RX surface footprint consisting of 8 key amino acid 
residues [263N, 264G, 265T, 266S, 268G (an insertion relative to wildtype AAV1), 269S, 270T, and 
274T (Vp1 numbering, relative to AAV1)] located within variable region I (VR-I), the loop connecting β 
strands, B and C in the VP monomer. As previously described, these residues are exposed on the surface 
of the full 60mer capsid and manifest as a cluster located on a protruding shoulder region located near the 
base of the larger protrusions at the three-fold axis of symmetry. This capsid structural feature serves as a 
hotspot for determining species, tissue and cellular tropism as well as antigenicity. This shoulder region 
containing the residues of the 1RX footprint are also located in close proximity to and at the edge of the 
depression at the two-fold axis of symmetry.   
Based on recent structural studies, we modeled the SIA receptor binding pocket on AAV1, 
containing eleven amino acid residues (S268, D270, N271, Y445, N447, G470, S472, V473, N500, T502, 
& W503, AAV1 Vp1 numbering) and located at the base of the three-fold spikes. On the capsid 
monomer, these residues span VR-I, VR-IV, and VR-V regions. We generated models of the AAV1RX 
capsid on which we overlaid the AAV1 SIA binding pocket residues (magenta) with the AAV1RX 
footprint residues (greencyan) (Fig. 3.7). From this overlay, we see that a single amino acid residue 
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overlaps between the two footprints (pale blue), a serine at position 268 (S268) in the AAV1 sequence, 
which has been mutated to a threonine in the AAV1RX footprint (270T, AAV1RX VP1 numbering). Out 
of the aforementioned eleven residues of the AAV1 SIA binding pocket, only six residues have been 
implicated as direct contact residues for binding the glycan – these are N447, S472, V473, N500, T502, 
and W503 (again, AAV1 VP1 numbering). The other five residues (S268, D270, N271, Y445, and G470) 
play an indirect role in mediating capsid-SIA interactions. When overlaid with the 1RX footprint, we see 
that the single overlapping residue that has been mutated in the SIA binding pocket, S268T (AAV1, VP1 
numbering), is not directly involved in binding SIA, but still contributes to capsid-SIA interactions. 
Furthermore, we see in our structural model that this overlapping (blue) residue lies nearby, but not 
directly at the mouth of the hole that forms the binding pocket upon the three-fold spike (Fig. 3.7, top 
inset). Additionally, we highlighted the six direct contact residues for SIA in red (Fig. 3.7, bottom inset). 
Within this region are residues directly involved in binding SIA were mutated in the AAV1-W503A and 
AAV1-N447S substitutions that were evaluated in this study. Consistent with previous studies, we found 
that single amino acid substitutions of these direct SIA contact residues results in greatly diminished and 
abolished SIA-binding ability for the W503A and N447S mutations, respectively. In conclusion, the 
AAV1RX footprint appears to have optimally engineered SIA recognition, which contributes to improved 
transport across the BBB.  
3.5. Discussion 
AAV serotypes utilize a broad range of cell surface glycans for attachment, which are, in part, 
key determinants of tropism. In particular, several AAV serotypes recognize different forms of SIA, with 
AAV1 binding α-2,3- and α-2,6- N-linked SIA within a pocket of residues located at the base of the three-
fold capsid surface protrusions283. Systemic administration of AAV1 results in a largely vascular and 
hepatic transduction profile, with negligible transport across the BBB and CNS transduction. However, 
engraftment of the 1RX footprint from AAVrh.10 onto the AAV1 capsid enables efficient BBB transport 
and robust neurotropism/CNS transduction, along with reduced vascular and peripheral tissue 
transduction.  
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Structural analyses revealed that the 8 residues of the 1RX footprint lay on a shoulder which is 
adjacent to the AAV1 SIA binding pocket located at the base of the three-fold protrusions. By modifying 
residues adjacent to the SIA footprint rather than direct contact residues, our data supports the notion that 
partially attenuated SIA interactions might contribute to capsid transport across the BBB. Accordingly, 
we propose a “Goldilocks” model, wherein the ideal SIA binding affinity, in conjunction with other 
contributing factors can influence CNS tropism of AAV capsids (Fig. 3.8). Specifically, capsids with 
strong SIA interactions show high levels of vascular sequestration and do not cross the BBB following 
systemic administration. Additionally, these capsids also transduce the liver efficiently. At the other end 
of the spectrum, capsids with either severely diminished or abolished SIA binding cross the BBB and 
transduce the CNS with only low-to-moderate efficiency, either due to reduced transport and/or 
transduction. The AAV1RX capsid displays an intermediate SIA binding phenotype, where it is not only 
effective at crossing the BBB, but also transduces cells in the brain parenchyma at a high level.  
It is important to note that our proposed model, while sufficient to explain the phenotypes of 
AAV1 based variants (and possibly those attributed to other SIA binding serotypes), cannot directly 
address the mechanism utilized by AAVrh.10 in crossing the BBB. As mentioned earlier, AAVrh.10 has 
recently been shown to recognize sulfated LacNac119. It is likely that LacNAc interactions influence the 
CNS tropism of AAVrh.10, and that mutations that interfere with these interactions could effectively 
attenuate BBB transport and/or CNS transduction. Such a scenario is corroborated in part by the 
attenuated phenotype displayed by AAVRX1 (reciprocal swap of AAV1 VR-1 residues onto AAVrh.10). 
Interestingly, however, AAVRX1 appears to retain the extremely high liver transduction phenotype of its 
parent. Another deviation from our model is the AAV1-N447S mutant, which despite abolished SIA 
binding and unable to traverse the BBB, displays improved AAVrh.10-like transduction in the liver and 
vasculature. One possible explanation is that the AAV1-N447S change constitutes an amino acid change 
identical to that observed on AAVrh.10 at that position, potentially imparting AAVrh.10-like features. 
However, whether AAVrh.10 utilizes a footprint similar to AAV1-SIA capsids to recognize the LacNAc 
receptor remains to be seen. Further, we note that capsid-glycan interactions only offer a partial 
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explanation for AAV tropism in general and acknowledge that other host factors such as AAVR or 
soluble serum factors might play a critical role in this regard.  
Our model is corroborated by other studies demonstrating that affinity for SIA is likewise 
inversely correlated with both virulence and spread for other viruses, such as other Parvoviruses and 
Polyomaviruses. This has been shown to be the case for the Minute Virus of Mice (MVM), another 
parvovirus, which also recognizes α-2,3-sialylated glycans as a critical step for infection287. Studies with 
SIA binding MVM mutants implicated differential SIA receptor affinity as a key determinant of virulence 
in mice288. Similarly, differential SIA receptor recognition and affinity has been reported as a key factor 
influencing CNS tropism and pathogenicity of Theiler’s virus, a Picornavirus as well as the systemic 
spread of Polyomaviruses in mouse289–291. Another facet of the aforementioned studies that support our 
conclusions is that similar SIA binding structural footprints, localized to the depression at the 2-fold axes 
of symmetry appear to be employed by other Parvoviruses, including MVM, CPV, and FPV36,55. This 
region has now been established as a key determinant of glycan receptor binding, antigenicity, tissue 
tropism and BBB transport by a multitude of studies in the literature.  
In summary, our studies establish that capsid-glycan interactions can influence AAV capsid 
transport across the BBB. While the current study hinges on AAV1 capsid variants and sialylated glycans 
as an example, it is plausible that other AAV serotypes and their cognate glycan receptors exhibit similar 
relationships that impact their CNS tropism. These findings could provide a structure-guided platform for 
engineering capsid-glycan interactions that enable optimal BBB transport and CNS transduction by AAV 
vectors for gene therapy of neurological disorders.      
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Figure 3.1. Structural models of AAV capsids used to interrogate the role of sialic acid interactions 
upon blood-brain barrier transport & CNS tropism. Three-dimensional molecular models of the 
whole 60mer capsid and of the trimer/three-fold axis of symmetry were generated for each capsid chosen 
for evaluating the impact on sialic acid interactions on crossing the blood-brain barrier: (A) AAV1RX, 
footprint for crossing the BBB from AAVrh.10 grafted onto AAV1, (B) AAVRX1, the corresponding 
residues from AAV1 grafted onto the AAVrh.10 backbone, (C) AAV1-N447S and (D) AAV1-W503A, 
two AAV1-based single amino acid changes previously shown to display defective capsid-sialic acid 
interactions. Amino acid residues derived from AAV1 are shown in gray, residues derived from 
AAVrh.10 are depicted in green-cyan, and single amino acid substitutions (AAV1-N447S & AAV1-
W503A) are shown in red. These structural models were visualized and generated using PyMOL. 
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Figure 3.2. Selected capsid variants display intermediate transduction profiles in a cell type-specific 
manner in vitro. Infectivity of capsid variants selected for differential sialic acid interaction potentials 
was tested by incubating each capsid variant virions on various CNS-derived cell lines at an MOI = 
10,000 vg/cell. Cells were lysed 48 h post infection to measure luciferase reporter expression. Cell lines 
evaluated include (A) Neuro2a mouse neuroblastoma cell line, (B) U87 human astrocytoma cells, and (C) 
MB114 mouse brain microvascular endothelial cells. Data are presented as means and error bars represent 
standard deviation (n = 3). 
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Figure 3.3. Capsid variants display differential sensitivities to removal of cell-surface sialic acid for 
both transduction and binding. (A) Transduction of capsid variants on MB114 cells following a 2 hour 
pre-treatment with either serum-free media or serum-free media containing 50 mU/mL Neuraminidase 
(Type-III, from Vibrio Cholerae). Viruses packaging a CBA-Luc reporter gene were incubated on MB114 
cells (MOI = 10,000 vg/cell) immediately following treatment. Cells were lysed 48 h post infection to 
measure relative luciferase transgene expression. Solid bars represent transduction in absence of enzyme 
while dotted bars represent transduction following treatment with neuraminidase. (B) Binding on MB114 
cells following treatment with or without neuraminidase. Cells were treated as described above with 
neuraminidase and were pre-chilled prior to incubation with virus for 1 h at 4 ⁰C. Cells were then lysed 
after three washes, DNA was extracted and the number bound viral genomes was quantified by qPCR. 
Binding data is shown and fold change. Data are presented as means ± SEMs (n > or = 3). For 
transduction data, an unpaired two-tailed t-test with Welch’s correction was performed to demonstrate 
statistical significance. ns, not significant; *, p < 0.05.
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Figure 3.4. Evaluating the impact of Sialic Acid binding on blood-brain barrier traversal and CNS transduction in vivo. Viruses displaying 
differential dependencies on sialic acid were produced packaging a CBh-scGFP transgene and were administered to mice at a dose of 5 x 1011 via 
tail vein injection and Immunostained brain sections were Immunostained for GFP expression 21 days later. Images from scans show transduction 
profiles for each variant (organized as higher to lower dependency on sialic acid, from left to right: AAV1, AAV1RX, AAV1-W503A, AAV1-
N447S, AAVRX1, and AAVrh.10) across multiple brain regions: (A) somatosensory cortex, (B) motor cortex, (C) pyramidal neurons of the 
hippocampus, (D) dentate gyrus, (E) striatum (caudoputamen), (F) thalamus, and the (G) hypothalamus. Images are representative of n > or = 3 
mice. Scale bars, 100 μm.
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Figure 3.5. Quantitation of neuronal and glial transduction profiles for capsid variants displaying 
differential dependencies on Sialic Acid. Three weeks after tail vein injections of vectors packaging a 
CBh-scGFP transgene at a dose of 5 x 1011 vg, brain sections were immunostained for GFP transgene 
expression, imaged, and relative neuronal and glial transduction levels were quantified by counting the 
number of GFP+ cells, as determined by cellular morphology. Relative transduction levels were quantified 
for (A) the cerebral cortex, (B) the hippocampus, and (C) the striatum. Data is shown as means and error 
bars represent standard deviation (n > or = 3).  
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Figure 3.6. Relative liver transduction mediated by capsid variants with differential sialic acid 
sensitivities. Three weeks after tail vein injections of vectors packaging a CBh-scGFP transgene at a dose 
of 5 x 1011 vg, liver sections were immunostained for GFP transgene expression. (A) GFP expression was 
imaged at 10% light intensity for mock treatment, AAV1, ARX, AAV1-W503A, and AAV1-N447S 
variants and (B) relative fluorescence was quantified with ImageJ and averaged across multiple images 
taken for multiple sections per liver sample. (C) GFP expression was imaged at 1% light intensity for 
mock treatment, AAV1, AAV1RX, AAVRX1, and AAVrh.10 (due to oversaturation of sensors by 
AAVRX1 & AAVrh.10). (D) Relative fluorescence levels were quantified as described above. Images 
taken at 10% light intensity were used for all quantifications of relative fluorescence. Data represents 
means ± SD (n = or > 3). One-way Anova followed by Tukey’s multiple-comparison test were carried out 
to demonstrate statistical significance relative to either AAV1 or AAVrh.10, for (B) and (C), respectively. 
ns, not significant. *, p < 0.05.  
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Figure 3.7. Structural analysis of the 1RX footprint within the context of the AAV1 Sialic acid 
binding pocket. Structural surface models overlaying the AAV1 sialic acid (SIA) binding pocket with on 
top AAV1RX. Homology models were generated using SWISS-MODEL and oligomers were 
subsequently generated using VIPERdb. PyMol was used to generate surface-rendered models of the 
AAV1-sialic acid binding pocket overlaid on top of (A) the AAV1RX capsid (60mer). (B) AAV1RX 
trimer-dimer showing the 1RX-SIA receptor footprint overlay within the context of both the three-fold 
and two-fold axes of symmetry. (C) Zoom-in of the AAV1RX-SIA binding pocket overlay within the 
context of a representative protrusion at the three-fold axis of symmetry. AAV1-derived residues are 
depicted in grey, the 8 residues of the 1RX footprint are depicted in greencyan, the residues of the AAV1 
SIA binding pocket are shown in magenta, residues present in both the SIA receptor footprint and the 
1RX region are shown in blue, and the residues in the SIA binding pocket that actually make direct 
contact with the SIA are shown in red.  
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Figure 3.8. Goldilocks model for the influence of capsid-sialic acid interactions on blood-brain 
barrier transport and CNS transduction. Here we suggest a goldilocks model which describes how 
capsid-SIA interactions influence the ability of systemically administered AAV capsids to cross the 
blood-brain barrier and transduce the CNS. On one end of the spectrum, capsids with strong SIA 
interactions (i.e. AAV1) undergo vascular sequestration and are prevented from crossing into the brain 
parenchyma and also transduce the liver. On the other end of the spectrum, capsids with severely 
diminished or abolished SIA-binding are either cross the BBB inefficiently and/or transduce the CNS 
with low-to-moderate efficiency, due to either reduced transport and/or transduction capabilities. The 
AAV1RX capsid, which shows an intermediate SIA-binding phenotype, however, seems to fall within a 
goldilocks zone, where it is not only effective at crossing the BBB but also at transducing cells in the 
brain parenchyma, at levels only slightly lower than seen for AAVrh.10.  
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
4.1. Overview 
 The overarching goal of this dissertation was to better understand structure-function correlates on 
the AAV capsid for blood-brain barrier (BBB) transport as well as central nervous system (CNS) 
transduction and tropism. Previous work elucidating structural determinants on the AAV capsid for 
tropism and immunogenicity have provided structural insights that have paved the way for efforts to 
engineer new AAV vectors with improved safety and efficacy21,55,66,72,75. A recent study made the pivotal 
discovery that several natural AAV serotyped capsids are able to traverse the BBB in mice and opened up 
the possibility for treating CNS diseases afflicting multiple brain regions with AAV vectors administered 
conveniently through intravascular injections257,292. Nonetheless, the precise capsid features that allowed 
for BBB transport and CNS transduction remained unknown.  
AAV is currently a leading vector for CNS gene therapy applications, bolstered by the success of 
many preclinical and clinical studies90,142,144,278,293. Substantial challenges nevertheless limit the 
therapeutic potential of CNS gene therapy. Foremost amongst these are insufficient transduction 
efficiencies and/or a lack of specificity in regards to tissue tropism for the current leading AAV vectors 
for CNS applications, namely AAV9 (and to a lesser extent AAVrh.10). These issues often necessitate 
extremely high dosages in order to achieve therapeutic expression, increasing scale up costs for vector 
production and can cause dose-related hepatotoxicity189,192,245. Thus, there is still a critical need to develop 
improved capsids for targeting the CNS via systemic administration, which is more convenient, less 
invasive, and better suited for achieving global CNS gene transfer, compared to other routes of 
administration, which often result in more punctate or limited localization of transgenes.  
Many application-based capsid engineering efforts, generally involving high-throughput shotgun 
approaches such as library generation combined with directed evolution, are continually being employed 
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in an attempt to develop improved vectors. Despite this, studies focused on expanding our understanding 
of AAV capsid biology and capsid-host interactions are currently lacking. The rational design of new 
capsid variants with improved CNS gene transfer following systemic administration requires a better 
understanding of structural features on the AAV capsid involved in virus-host interactions, such as those 
which occur at the neurovascular unit. Therefore, we focused on understanding capsid structure, 
dissecting structural determinants and capsid-host interactions important for AAV transport across the 
BBB and CNS gene transfer.  
4.2. Mapping Structural Determinants for Transport of AAV across the Blood-Brain Barrier. 
 In chapter 2, we set out to identify the structural features on the capsid that confer the ability of 
some AAV serotypes to cross the BBB and penetrate the brain parenchyma. To address this question, we 
first generated a chimeric capsid library through DNA shuffling, using AAVrh.10 and AAV1 as parental 
capsids, which either can or cannot cross the BBB, respectively. In contrast to other studies using high-
throughput strategies such as library generation and directed evolution to evolve ideal vectors, we chose 
not to subject our library to selective pressures. Instead, we isolated individual chimeric variants from our 
library and screened them for their ability to cross the BBB and transduce the CNS in vivo. We found two 
variants, AAV1R6 and AAV1R7, which crossed the BBB and transduced multiple regions in the brain 
following intravenous injections. These capsids were also found to preferentially transduce neurons while 
showing reduced transduction of glial and endothelial cells in the parenchyma.  
Using structural cues, excluding non-surface-exposed residues and residues implicated in genome 
packaging or assembly rather than for tropism or transduction, we were able to identify a minimal 
footprint consisting of 8 residues from AAVrh.10 that are important for crossing the BBB. Through 
grafting this 8-residue footprint onto AAV1, we were able to rationally engineer the AAV1RX capsid, 
which phenocopied AAV1R6/7 in terms of BBB transport and the ability to preferentially transduce 
neurons throughout the brain. Lastly, we found that AAV1RX (in addition to AAV1R6/7) retains the 
cardiac transduction profile shared by its parental capsids and is detargeted from nearly all other 
peripheral tissues, including the liver, as assessed by in vivo transduction assays and biodistribution of 
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viral genomes. Lastly, we found that this footprint was shared, to varying degrees, across other naturally 
neurotropic capsids (i.e. AAVrh.8, and partially in AAV7, AAV8, AAVrh.39, and AAVrh.43). This 
further supports the importance of these 8 residues and suggests that completion of the footprint may 
enhance BBB transport and CNS transduction for some serotypes.  
 While the mechanism of action for how the 1RX footprint affords transport across the BBB is 
unknown, these findings simultaneously advance our understanding of AAV biology and provide a 
structure-guided platform for rationally engineering novel CNS-targeted AAV vectors with the potential 
to provide therapeutic gene expression at a lower dose, thus improving both safety and efficacy. 
Additionally, AAV1RX is a novel AAV capsid with therapeutic potential that is ideally suited for CNS 
indications, due to its ability to traverse the neurovascular unit and efficiently transduce the brain 
parenchyma, with simultaneous detargeting from peripheral tissues such as the liver, following systemic 
administration. 
Furthermore, these findings highlight the synergy between using high-throughput techniques such 
as library generation combined with structure-guided design. Together, they provide the potential to 
simultaneously elucidate AAV biology while generating improved AAV vectors. By providing a 
structural clue in the mystery of how AAV capsids cross the BBB, the discovery of the 1RX footprint will 
hopefully serve as a springboard for further dissection of capsid-host interactions which occur to promote 
or restrict transvascular transport across the neurovascular unit.  
4.3. Influence of Capsid-Glycan Interactions on Blood-Brain Barrier Transport, Neurotropism, and 
Transduction 
 Following up the discovery of the AAV1RX footprint that enables efficient BBB transport, we 
wanted to shed light on the mechanisms and potential capsid-host interactions involved in this phenotype. 
Structural analyses mapped the residues of the 1RX footprint to a shoulder adjacent to the AAV1 SIA 
binding pocket located at the base of the 3-fold protrusions. Thus, in chapter 3 of this dissertation, we set 
out to further understand the influence of capsid-SIA interactions on AAV transport across the BBB as 
well as CNS tropism and transduction. We characterized several AAV capsid variants which were found 
 86 
to exhibit differential sensitivities to enzymatic removal of cell surface SIA in vitro and in vivo. We found 
an inverse correlation between capsid-SIA interactions and BBB transport as well as CNS 
transduction/tropism. We additionally observed a mostly direct correlation between SIA dependency and 
both vascular and hepatic transduction phenotypes, although some variation was seen.  
Structural analyses in which the 1RX and AAV1-SIA footprints were overlaid revealed that the 
mutations we made through engraftment of the 1RX footprint are adjacent to the direct contact residues 
for SIA. We found that mutating direct contact residues for SIA results in either greatly weakening or 
ablating capsid-SIA interactions. By modifying adjacent residues in the 1RX footprint, rather than the 
direct contact residues themselves, we seem to have instead only partially attenuated SIA interactions. 
Thus, the 1RX residues seem to tweak capsid-SIA interactions to promote, while not entirely accounting 
for, the phenotype observed for AAV1RX, in terms of BBB transport and neurotropism.  
 We concluded chapter 3 by proposing a “Goldilocks” model, in which the ideal glycan binding 
affinity, in conjunction with other factors, can impact the ability of AAV capsids to cross the BBB. 
Briefly, we found that capsids with a high SIA dependence are restricted to the vasculature (as well as the 
liver). On the other side of the spectrum, capsids with very low SIA dependence cross the BBB and 
transduce the CNS with very low efficiency, with mostly reduced vascular and liver transduction. We 
found that AAV1RX, which displays more moderate SIA dependency seems to lie in a “Goldilocks 
zone”, where it is able to efficiently cross the BBB and efficiently transduce the parenchyma, while being 
simultaneously detargeted from vasculature and the liver. Nonetheless, this model is insufficient to 
describe capsids which do not recognize SIA, such as AAVrh.10 and AARX1, which is the reciprocal 
swap relative to AAV1RX. Moreover, we found that grafting the corresponding residues from AAV1 
onto the AAVrh.10 capsid attenuated BBB transport efficiency and CNS transduction compared to 
AAVrh.10. Thus, the AAV1RX phenotype cannot be solely explained by altered capsid-SIA interactions. 
Rather, our data suggests the involvement of other mechanisms important for BBB transport, such as 
interactions with the sulfated LacNac receptor for AAVrh.10 or interactions between the capsid and other 
host factors such as a soluble serum protein.  
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In conclusion, our findings shed light on the mechanisms governing AAV CNS tropism, 
providing a structure-guided platform for fine-tuning capsid-glycan interactions in order to effect tropism 
and transduction profiles, such as to promote BBB traversal for CNS gene therapy. Furthermore, while 
most structural-guided rational design efforts for capsid engineering focus on modifications to known 
hotspot determinants of tropism, such as the three-fold protrusions themselves, our data demonstrates the 
potential for fine-tuning precise interactions to effect the aforementioned phenotypes by modifying 
contextual landscapes surrounding these regions, pointing towards the 2-fold axis of symmetry and 
regions adjacent to the three-fold protrusions as areas for investigation that are amenable to mutation in 
order to modulate, but not abolish desirable phenotypes, such as transvascular transport. 
4.4. Future Directions 
In this dissertation, we sought to enhance our understanding of structure-function correlates on 
the AAV capsid for BBB transport, neurotropism, and transduction of the brain parenchyma following 
systemic (intravascular) administration. We set this as our goal in an effort to guide rational and structure-
guided design of improved AAV vectors for neurological gene therapy applications (particularly for those 
which require widespread gene transfer throughout the brain). Given the discovery of several naturally 
neurotropic AAV serotypes, along with current limitations of CNS gene therapy due to the BBB, we 
resolved to identify structural determinants for transvascular transport. We utilized a high-throughput 
library based strategy in tandem with structural analyses to identify structural determinants for these CNS 
phenotypes and used the discovery of a structural footprint for BBB transport to engineer the synthetic 
and neurotropic AAV1RX capsid, an ideal candidate for neurological gene therapy applications in the 
future. We further expanded on this in our subsequent study where we drew a link between SIA binding 
and BBB transport, glimpsing a partial mechanism through which the 1RX footprint may afford BBB 
transport. These findings suggested a model for the influence of capsid-glycan interactions on BBB 
traversal and CNS transduction. Further, these studies gave us a better understanding of capsid-host 
interactions and identified key targets, on the capsid side (1RX footprint) and the host side (glycan 
interactions), that are involved in the mechanism by which AAV capsids cross the BBB. In this way, the 
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identification of these key targets for evaluation may act as a stepping stone to inform future studies 
which will hopefully build upon these findings and further unravel this mysterious mechanism.  
Mechanism of transvascular transport for AAV across the blood-brain barrier and defining 
interactions at the neurovascular unit. Mapping of the 1RX footprint for BBB transport from AAVrh.10 
provides a clue as to the structural elements involved in BBB transport; however, the actual mechanism of 
AAV transport across the neurovascular unit remains a mystery. Perhaps the largest remaining question - 
how do AAV1RX and other AAV capsids engage the neurovascular unit, and are these interactions 
serotype specific? Furthermore, experiments using intracerebroventricular (ICV) injections of AAV1RX 
should be performed to assess the transduction properties and cellular tropism of AAV1RX in the brain 
outside the context of BBB transport, and will also assess the ability of AAV1RX to spread within the 
brain parenchyma. Future studies should be aimed at uncovering the mechanism(s) through which 
AAV1RX, as well as other neurotropic capsids (i.e. AAV9, AAVrh.8, AAVrh.10, etc.), cross the BBB 
and should be focused on defining how these capsids engage the neurovascular unit and whether this 
engagement is capsid-specific. 
We cannot rule out the possibility that AAV crosses through disrupting BBB integrity, i.e. 
mediated through inflammatory effects which may weaken tight junction complexes between endothelial 
cells (i.e. through weakening tight junctions between endothelial cells); however, this scenario seems 
unlikely due to the favorable immune profile of AAV, lack of supporting data, and the lack of viral genes 
to facilitate such a process. In a more likely theory, AAV transport across the BBB is thought to occur via 
receptor-mediated transcytosis157. While current in vitro cell culture-based BBB models fail to faithfully 
recapitulate the in vivo neurovascular unit, future studies involving cultured endothelial cell monolayers 
(and perhaps other co-cultures, such as astrocytic end-feet, pericytes, etc.) could play a role in pinpointing 
differences in cellular uptake and trafficking routes between AAV1RX and AAV1/rh.10, as well as more 
defined serotypes like AAV2 & AAV9. The abilities of AAV2, AAV9 and bovine AAV (BAAV) to 
undergo transcytosis across monolayers of both endothelial and epithelial cells in vitro has been 
characterized. It was found to be an active process, is serotype-dependent and that vectors are still 
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transduction-competent following apical-to-basolateral transport294,295. Furthermore, these studies 
provided evidence that transduction and transcytosis may occur through independent and possibly 
competitive cellular routes296. This theory makes sense in the context of AAV1/rh.10/1RX, where it is 
tempting to speculate that AAV1 may exclusively utilize a transduction pathway in the endothelium. In 
contrast, it is possible that AAV1RX preferentially undergoes trafficking routes targeted for transcytosis, 
while AAVrh.10 may use both routes ubiquitously. Future experiments could support or deny this theory 
and could focus on ascertaining capsid-host factor interactions that may be involved in these intracellular 
pathways. Additionally, future directions should include dissecting the 1RX mechanism through co-
administering AAV with various pharmacological agents which block various steps in the 
transduction/transcytosis/trafficking pathways and to look for differential effects between AAV1RX & 
AAV1/rh.10. We know that glymphatics affect the spread of AAV within and clearance from the CNS; 
however, it remains to be determined whether BBB transport and/or CNS transduction are also impacted 
by glymphatics239. Moreover, we do not know whether AAV1RX/rh.8/rh.10 are capable of undergoing 
axonal transport, either unidirectional or bidirectional, which should be addressed in future studies.  
Many questions still remain regarding the precise mechanism of how AAV capsids cross the BBB 
and the interactions involved. While thought to undergo receptor-mediated endocytosis, it is still 
unknown precisely how AAV1RX gains entry into the brain. It is possible that AAV1RX may bind 
another host factor as part of its mechanism, and we still do not know how AAV1RX interacts with the 
individual components of the BBB. If it does undergo receptor-mediated endocytosis across the 
vasculature, is its interaction limited to vascular endothelial cells, or is this transport impacted by 
interactions between the AAV1RX capsid and other components of the neurovascular unit? Vascular 
endothelial cells and their tight junctions are not the only components present at the BBB. Rather, the 
neurovascular unit also consists of vascular smooth muscle cells and pericytes, which both line the 
endothelium, as well as astrocytic end feet, the basement membrane, and the highly glycosylated 
extracellular matrix224,297. Interactions likely occur between AAV1RX (as well as for other capsids) and 
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these components, which may either facilitate or hinder transvascular transport at the BBB. Dissection of 
these interactions should be the focus of future studies, as they are critical gaps in our knowledge. 
Translatability of the 1RX footprint to enhance blood-brain barrier transport and CNS 
transduction for other AAV serotypes. We know that engraftment of the 8 key residues of the 1RX 
footprint from AAVrh.10 onto the AAV1 capsid affords BBB transport and CNS transduction; however, 
we don’t know if this footprint can be grafted onto other serotypes and whether it will be sufficient to 
confer this CNS phenotype. Firstly, we do not know whether other residues in the AAV1 (or AAVrh.10) 
VP3 capsid sequence(s) act synergistically with the 1RX footprint to enable robust BBB transport/CNS 
transduction. Sequence alignments comparing multiple naturally occurring neurotropic capsids reveal that 
this footprint is either entirely conserved (in the case of AAVrh.8/rh.39) or mostly conserved (i.e. for 
AAV7/8/9/rh.43)284. It is tempting to speculate that completion of this footprint (i.e. mutation of 
mismatched residues to the equivalent in AAVrh.10) may enhance transvascular transport and CNS 
transduction for these capsids. Nonetheless, we do not know whether engraftment of the 1RX footprint is 
compatible with more divergent serotypes (i.e. AAV2/3/4/5). Studies in the future should focus on 
answering these questions regarding the translatability of the 1RX footprint to other capsid variants. 
Determining the role of the blood-cerebrospinal fluid and cerebrospinal fluid-brain barriers, and 
the choroid plexus in regards to brain penetration by systemically administered AAV vectors. While the 
BBB is a critical interface between the brain and the vasculature, it is not the only way that a virus could 
enter the brain from the bloodstream. It’s also possible that AAV could gain access to the brain at regions 
without a strong BBB, at circumventricular organs such as the subfornical organ and the medial regions 
of the hippocampus. Here, AAV may travel through the extracellular spaces and the interstitial fluid. 
Furthermore, while we have demonstrated that the 1RX footprint affords efficient BBB transport, we 
cannot rule out the possibility that AAV1RX may be capable of crossing the blood-cerebrospinal fluid 
barrier as well (BCSFB), although our data shows low transduction of the choroid plexus and no 
indication of involvement with a CSF intermediate for AAV1RX. The BCSFB predominantly consists of 
a monolayer of choroid plexus epithelial cells, which separates the two fluids. The choroid plexus is the 
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brain region which generates CSF, and leaky capillaries within the choroid plexus are involved in 
regulating the transport of substances from the bloodstream into the CSF298. We observed robust 
transduction of choroid plexus epithelial cells mediated by AAVrh.10, and to a lesser degree, AAVRX1 
(and to an even lesser degree AAV1-N447S). None of the other capsid variants showed a similar capacity 
to transduce the choroid plexus, suggesting that capsid-SIA interactions do not mediate these phenotypes. 
These observations are further corroborated by other studies showing similar transduction of the choroid 
plexus for AAVrh.10 and transduction gradients at the periventricular spaces98,254. 
 Our preliminary data (Fig. 4.1) shows that AAVrh.10 and AAVRX1 (as well as AAV1-N447S, 
to a lesser degree consistently mediate a gradient-like transduction pattern in specific areas of the brain 
located nearby the CSF-containing ventricles, such as at the periphery of the somatosensory cortex 
(decreasing in density of GFP+ cells as you move away from the periphery, from cortical neuron layers 1-
5). We observe a similar transduction gradient at the paraventricular nucleus of the thalamus and the 
medial habenula of the hypothalamus, with a high density of GFP+ cells present in these regions adjacent 
to the third ventricle, with the density of GFP+ cells showing a sharp decrease as you move away from 
the third ventricle and into the mediodorsal, intermediodorsal, and central lateral nuclei of the thalamus as 
well as the lateral habenula (Fig. 4.1). Together, these data indicate that AAVrh.10 may be capable of 
utilizing a CSF intermediate in order to achieve its robust global CNS transduction. Whether AAVrh.10 is 
able to cross both the BBB as well as the blood-CSF barrier (and the CSF-brain barrier) and/or is 
transported from the parenchyma into the CSF and undergoes CSF-mediated spread in the brain in order 
to transduce the CNS are currently unknown and should be the focus of future studies298.   
Expanding our understanding of the relationship between capsid-glycan interactions and both 
BBB transport and CNS transduction. In Chapter 3, we demonstrated an inverse correlation between the 
dependence of capsids on SIA for binding and transduction and the ability to cross the BBB. Furthermore, 
we demonstrated a direct correlation between SIA dependence and both vascular and liver 
transduction/sequestration, although we observed some deviation observed for this trend. Nonetheless, 
future directions should expand on this analysis, through methods such as characterizing additional capsid 
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mutants across the SIA sensitivity spectrum, in order to strengthen this evidence. Additionally, more 
comprehensive biochemical analyses, such as saturation binding experiments and surface plasmon 
resonance should be carried out in order to more precisely determine binding affinities and correlate these 
with BBB transport and CNS transduction.  
A further hypothesis is that the 1RX footprint may mediate other interactions which depend upon 
involvement of SIA interactions in the context of AAV1. Thus, it is possible that glycan interactions for 
other capsids may play either a synergistic or antagonistic role in enabling a similar CNS phenotype. 
Thus, it is possible that the 1RX footprint may not work at all for some serotypes, or that it may only 
work for some serotypes in the context of altered (i.e. attenuated) glycan interactions. As mentioned 
before, a sulfated N-acetyllactosamine (LacNac) has recently been identified as the receptor for 
AAVrh.10, and we speculate (in chapter 3) that interfering with these interactions attenuates BBB 
transport and/or CNS transduction. Similar studies focused on the AAVrh.10 LacNac interaction may 
help further our understanding of the neurotropic properties of AAVrh.10 within the context of BBB 
traversal and biology in the CNS as well as for peripheral tissues such as the liver. 
Future studies should be focused on illuminating these relationships, and should also focus on 
determining to what extent this Goldilocks model for capsid-SIA interactions can be extended to fine-tune 
various other capsid-glycan interactions, such as those for AAV9 and galactose, AAV2 and HS, and 
AAVrh.10 and LacNac. It is tempting to speculate on the possibility of generating a matrix across the 
spectrum of various capsid-glycan receptor pairs in order to find similar goldilocks zones for BBB 
transport, specific tropisms, transduction profiles, or any other phenotype of interest. 
Effect of sialic acid linkage and species-specific glycosylation patterns on blood-brain barrier 
transport and central nervous system transduction. Multiple other variables, such as the different forms, 
linkages, and patterns of glycans add a further layer of complexity to our model for capsid glycan 
interactions. All of these variables are likely to play a role in determining these CNS phenotypes and 
further studies will be needed to shed light on these complex carbohydrate interactions. Excluding other 
capsid-glycan pairs, this complexity can be appreciated looking just at SIA. For example, what are the 
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effects of altering the preference of a given capsid for either specific linkages of SIA (i.e. α-2,3- or α-2,6- 
N-linkages) or specific sugar content of SIA (i.e. skewing preference towards either the mammalian 
Neu5GC or the human-specific Neu5AC variant of SIA)?  For example, preliminary data from our lab has 
shown evidence of differential transduction profiles for AAV vectors in a mouse model of human 
glycosylation. Specifically, we observed decreased liver transduction for AAV6 and muscle transduction 
for AAV1, corroborated by decreased in vitro transduction for both following metabolic incorporation of 
the human variant Neu5AC (unpublished data).  These phenomena should be investigated in future 
studies which could take advantage of the well-characterized CMAH (cytidine monophosphate-N-
acetylneuraminic acid hydroxylase) knockout mouse model which recapitulates human glycosylation 
patterns. Furthermore, can these specific interactions be manipulated in order to modulate certain 
phenotypes? And does AAV1RX demonstrate skewed preferences for SIA identity and/or linkage?  
Identification of potential host factor interactions for the 1RX footprint. In proposing our 
“Goldilocks” model to describe the effect of capsid-SIA interactions, we have provide a partial 
explanation for the mechanism by which the 1RX footprint affords BBB traversal and CNS transduction; 
however, other contributing factors likely also play a role. We suspect that BBB transport is mediated 
through interactions between AAV1RX and currently unknown host factors, such as soluble proteins in 
circulation or alternatively recognition of (likely glycosylated) cell surface transmembrane proteins. For 
instance, does AAV1 bind a sialylated surface protein on brain microvascular endothelial cells which 
shuttles the virion down a transduction route, whereas perhaps AAVrh.10 and AAV1RX bind a 
transmembrane protein receptor which destines the virion for transcytosis across the vasculature? 
Furthermore, it is possible that the 1RX footprint mediates an interaction that is entirely separate from 
those used by either parent. Similarly, what role, if any is played by secondary receptors, i.e. the recently 
discovered AAV receptor (AAVR), integrins and various co-receptor interactions in effecting BBB 
transport and CNS transduction? 
Future studies should focus on identifying interaction partners for the 1RX footprint in order to 
elucidate the mechanism(s) that result in its CNS phenotype. For instance, experiments could be 
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performed involving immunoprecipitation to pull-down host factors which bind the AAV1RX capsid 
exclusively versus control (AAV1/rh.10) capsids followed by mass-spectrometry to identity these factors. 
For example, these types of experiments could be performed in vitro on primary cultures of brain 
microvascular endothelial cells and potentially in vivo as well (i.e. using brain lysates). Additionally, pull-
down studies such as these could be carried out to identify host factors interacting exclusively with the 
1RX motif in serum or CSF samples. Along these lines, I have performed preliminary pulldown 
experiments using beads attached to lectins which bind either sialylated or galactosylated glycoproteins in 
murine CSF samples, to discover potential binding partners for either SIA recognizing capsids (i.e. 
AAV1/4/5/6/1RX) or GAL recognizing capsids (i.e. AAV9). This pull-down was followed up by mass 
spectrometry and the analysis of resulting peptides (based on number of reads) identified lactotransferrin 
and SPARC-like protein 1 (SPARCL1) proteins as potential binding partners to be validated in future 
experiments. Future studies such as these may discover a receptor involved in transvascular transport 
processes, such as the well-characterized transferrin receptor or alternatively discover that 1RX may bind 
a soluble serum factor which facilitates uptake and transport across the vasculature, such as transferrin.  
Concluding remarks. Overall, the means by which AAV1RX and naturally neurotropic AAV 
capsids engage the neurovascular unit at the BBB and gain entry into the brain parenchyma following 
systemic administration remains elusive. The mechanism(s) responsible and many unknown variables 
remain to be resolved - i.e. unidentified capsid-host factor interactions, the possibility of capsid-dependent 
methods, and the relative roles of capsid-glycan interactions. Whether AAV capsids are capable of 
employing routes other than BBB transport, such as transport through the BCSFB, the choroid plexus, 
and/or circumventricular organs with a more permeable BBB, as well as the influence of glymphatics, 
must all be resolved through future studies. Similarly, the determinants of CNS tropism at the tissue, 
cellular, and subcellular population (i.e. different neuronal populations) levels remain to be discovered. 
 In this dissertation, we focused on expanding our understanding of structure-function correlates 
on the AAV capsid for BBB transport. We did this in chapter 2 by using high throughput library-based 
methods and an in vivo screen combined with structural analyses to map a structural footprint from 
 95 
AAVrh.10 that is important in BBB traversal. Through providing this structural insight, we rationally 
engineered the neurotropic AAV1RX capsid, which is detargeted from peripheral tissues such as the liver, 
and serves as an idyllic vector for achieving therapeutic gene transfer to the CNS through systemic 
administration. Hopefully, future preclinical studies will be carried out in large animal models, such as 
non-human primates, to validate the safety and efficacy of AAV1RX as a gene therapy vector.  
Subsequently performing a comparative analysis of capsids with differential dependencies on 
SIA, in chapter 3, I found that the ability to cross the BBB was inversely correlated with the SIA 
dependence of a given capsid. These results prompted me to propose a model to describe the influence of 
capsid-glycan interactions on BBB transport and CNS transduction. Future studies will hopefully provide 
additional evidence to either disprove or confirm this model and possibly expand upon it, especially 
within the context of other capsid-glycan interactions.  
These findings are a small but important step towards a more complete understanding of the 
principal mechanisms and capsid-host interactions which promote AAV transport across the BBB, and 
provide clues as to some of the players involved. Other studies to dissect the potential involvement of 
other host-factors, and identification of such factors, will be critical in elucidating this mechanism. 
Perhaps some of these lessons can be applied to improve transvascular transport and obtain higher 
transduction levels for other capsids in other tissues, such as skeletal muscle or cardiac tissues. 
Engineering improved gene therapy vectors to treat neurological diseases, which can be administered 
systemically and target the entire brain parenchyma is critical. Additionally, such efforts require a better 
understanding of AAV capsid-host interactions, such as how AAV engages the neurovascular unit. 
Therefore, it is imperative that future studies build upon these findings in order to resolve the mystery of 
how AAV capsids cross the BBB to transduce the brain parenchyma. 
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Figure 4.1. Transduction of the choroid plexus and paraventricular nucleus of the thalamus 
following intravenous administration. Viruses displaying differential dependencies on sialic acid were 
produced packaging a CBh-scGFP transgene and were administered to mice at a dose of 5 x 1011 viral 
genomes via tail vein injection. Brain sections were immunostained for GFP expression 21 days later. 
Images from scans show transduction of the choroid plexus/paraventricular nucleus of the thalamus for 
each variant (organized as higher to lower dependency on sialic acid, from left to right: AAV1, 
AAV1RX, AAV1-W503A, AAV1-N447S, AAVRX1, and AAVrh.10). Scale bars represent 100 μm. 
Images are representative of n > or = 3.  
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